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1 Introduction 
1.1 Macrophage Migration Inhibitory Factor 
1.1.1 MIF – A Historical Overview 
A soluble factor that inhibits the migration of immune cells in vitro was mentioned as 
early as 1932, in reports by Rich and Lewis (1). But the actual discovery of the 
macrophage migration inhibitory factor (MIF) protein occurred about 30 years later. 
While developing an assay in 1962 to measure the migration of peritoneal cells in 
capillary tubes, scientists rediscovered MIF (2). In 1966, David et al., and Bloom and 
Bennett independently identified MIF as one of the first cytokines (3, 4). The first 
function attributed to MIF was its inhibitory action on the random migration of 
macrophages in the delayed-type hypersensitivity reaction (3, 5). Subsequently, MIF 
was also shown to activate macrophages leading to increased cell surface adhesion 
and phagocytosis (6). Nevertheless, the molecular mechanisms underlying MIF’s 
functions remained unknown. Several years passed without successful isolation of 
pure MIF. Samples were contaminated with lipopolysaccharide (LPS), interferon 
(IFN) γ and interleukin (IL) 4, which possess similar migration inhibitory properties 
as MIF, making it difficult to distinguish MIF’s actions (7-9). A breakthrough came in 
1989 when a human T-cell MIF cDNA was first isolated and cloned. The expressed 
polypeptide had the expected molecular weight of 12.5 kDa (10). In 1993, Bernhagen 
et al. first cloned and purified murine MIF, which they showed was released from 
anterior pituitary cells in response to bacterial LPS (11). Following the expression of 
biologically active MIF in E. coli, detailed studies on its structure and functions were 
performed (12). Macrophages, T cells and the pituitary gland were observed to be a 
major sources of MIF production, releasing the cytokine after treatment with pro-
inflammatory stimuli such as LPS, tumor necrosis factor (TNF) α, IFNγ (13), gram-
positive exotoxins (toxic shock syndrome toxin-1 (TSST-1) and streptococcal 
pyrogenic exotoxin A (SPEA)) (14), mycobacterial products (15), malarial pigment 
(hemozoin) (16), and even after stimulation with low concentrations of anti-
inflammatory glucocorticoids (17). In 1999, a MIF knockout mouse was constructed, 
demonstrating that deletion of the mif gene reduces inflammatory responses (18). The 
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discovery of the MIF cell surface receptor CD74 (19) and, later, of the chemokine 
receptors CXCR2, and CXCR4 (20) helped to further our understanding of the 
mechanisms for MIF signaling. Reports of an association between high expression 
MIF alleles on the one hand and inflammatory disease susceptibility and severity on 
the other further emphasized the role of MIF in disease pathology (21-25). 
 
1.1.2 Molecular Mechanisms of MIF Action 
1.1.2.1 MIF is a Cytokine 
The term cytokine describes a functional class of protein mediators, which are 
produced in a regulated fashion to affect the activation and differentiation of the 
immune response. Once released, they usually act in an autocrine or paracrine manner 
leading to an ensuing activation of the innate (dendritic cell, monocyte/macrophage) 
or the adaptive (T and B cell) immune response characterized by further production of 
an array of immunoregulatory cytokines. Cytokines display the cardinal properties of 
pleiotropism, synergy, antagonism, and redundancy, aggravating the understanding of 
their precise function in different physiologic and pathologic contexts. 
Discovered in the early 1960s as one of the first cytokines to be described, MIF 
was first considered a T cell cytokine, regulating the activation of T cells induced by 
mitogenic or antigenic stimuli (14, 26). Monocytes and macrophages that had 
previously been considered to be the target of MIF action were observed to be a 
significant source of MIF. Upon pro-inflammatory stimuli, macrophages were 
reported to produce TNFα and nitric oxide (NO) (13, 27). Subsequently, more cell 
types, such as eosinophil granulocytes, B cells and mast cells, were identified to be 
involved in MIF action (28-30). Even gastrointestinal colorectal adenoma cells and 
prostatic adenocarcinoma cells showed increased MIF levels, suggesting 
protumorigenic activity of MIF (31, 32). Consistent with its definition as a cytokine, 
MIF has been shown to exhibit various molecular modes of action relevant to 
antimicrobial host defense, which are summarized in Figure 1 and further 
characterized in the subsequent paragraphs.  
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Figure 1: Molecular mechanisms of MIF. MIF binding to the CD74/CD44 receptor complex leads to 
ERK-1/2 activation, which results in downstream PGE2 production via cPLA2 and COX-2 activation 
(1). Moreover, phosphorylation of ERK-1/2 indirectly upregulates TLR4, the cell surface receptor for 
gram-negative bacteria, through stabilization of Ets transcription factor (2). This results in the 
upregulation of immune response genes and, thus, production of pro-inflammatory cytokines and 
adhesion molecules. MIF also protects cells from apoptosis by inhibiting p53 via COX-2 (3). The 
counter-regulation of MIF on the effects of glucocorticoids is summarized in 4. MIF antagonizes 
glucocorticoid actions by facilitating the degradation of the NF-κB inhibitor IκB, and also of MKP-1. 
Abbreviations: ERK-1/2, p44/p42 extracellular signal-regulated kinases; PGE2, prostaglandin E2; 
cPLA2, cytosolic phospholipase A2; COX-2, cyclooxygenase-2; TLR4, toll-like receptor 4; Ets, E-
twenty six; NF-κB, nuclear factor kappa B; IκB, inhibitor of NF-κB kinase; MKP-1, MAPK 
phosphatase 1. Figure taken from (33). 
 
1.1.2.2 MIF is a Hormone 
In 1994, MIF was discovered also to act in a hormone-like fashion. Bernhagen et al. 
identified MIF as a major secreted protein released by anterior pituitary cells in 
response to septic shock induced by LPS administration (11). MIF expression in 
corticotrophic and thyrotrophic cells of the anterior pituitary gland and its 
colocalization in secretory granules with either adrenocorticotrophic hormone 
(ACTH) or thyroid-stimulating hormone (TSH) further supported MIF’s role in the 
hypothalamic-pituitary-adrenal (HPA) axis (34). Pituitary-derived MIF enters the 
bloodstream after infectious or stressful stimulation to the organism, leading to an 
increase of circulating MIF concentrations. A systematic analysis of MIF expression 
in various organs of the rat showed the release of MIF 6 hours after LPS 
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administration, accompanied by the induction of MIF mRNA and, at 24 hours, the 
restoration of immunoreactive, intracellular MIF (30). In human serum the 
physiological MIF serum concentration is between 1 and 15 ng/ml, whereas 
concentrations up to 350 ng/ml are reached upon inflammatory stimulation (11). 
 
1.1.2.3 Non-Classical Secretion 
In contrast to most cytokines, MIF is constitutively expressed and stored in 
intracellular pools and, therefore, does not require de novo protein synthesis before 
secretion into the extracellular milieu (30). In 1993, Flieger et al. demonstrated that 
MIF secretion occurs via a non-classical export route for protein export, suggesting 
the involvement of the ATB binding cassette (ABC) A1 transporter (35). More 
recently, Merk et al. identified the Golgi-associated protein p115 as an intracellular 
binding partner of MIF and provided evidence for the p115-dependent release of MIF 
from human macrophages (36). It was shown that the small molecule MIF inhibitor 4-
IPP targets MIF secretion by influencing the interaction between MIF and p115. 
 
1.1.2.4 Receptors 
Cytokines bind to their cell surface receptors and trigger an intracellular signaling 
cascade. In 2003, CD74 was discovered as the cell surface receptor of MIF (19). 
CD74 is a 31-41 kDa Type II transmembrane protein and the cell surface form of the 
Class II-associated invariant chain. Leng at al. reported that the cell surface 
expression of CD74 was required for MIF-dependent ERK-1/2 phosphorylation, 
prostaglandin E2 (PGE2) production and cell proliferation (37). CD74 lacks any 
obvious signal transduction domain; therefore, the molecular mechanisms of MIF 
signaling were not evident for some time. In 2007, CD44 was identified as an integral 
member of the CD74 receptor complex leading to MIF signal transduction. MIF 
binding to the receptor complex resulted in the serine phosphorylation of CD74 and 
CD44 at the intracytoplasmic domain (38). Being a widely expressed, polymorphic 
transmembrane protein with known tyrosine kinase activation properties (39), CD44 
then activates members of the Src-family tyrosine kinases, leading to downstream 
ERK phosphorylation. Both receptors, CD74 and CD44, have been shown to be 
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necessary for MIF protection from apoptosis (38), which further emphasized CD44’s 
role in MIF signaling. 
In 2007, Bernhagen et al. identified the chemokine receptors CXCR2 and 
CXCR4 as non-cognate receptors for MIF (20). MIF competed with cognate ligands 
and directly bound to CXCR2. CXCR2 and CD74 were shown to co-localize, 
suggesting a MIF signaling pathway via a CD74/CXCR2 receptor complex. Both 
receptors were required for MIF-dependent monocyte arrest in atherosclerotic arteries. 
By activating both CXCR2 and CXCR4, MIF was reported to function as a major 
regulator of inflammatory cell recruitment and atherogenesis. In 2010, Tarnowski et 
al. first showed in human rhabdomyosarcoma cells that MIF also stimulates the 
CXCR7 receptor, resulting in the modulation of tumor metastasis (40).  
 
1.1.2.5 Signaling via ERK-MAPK 
In 1999, Mitchell et al. discovered that cell stimulation by MIF let to transient (rapid, 
within minutes) and sustained (prolonged, for hours) phosphorylation of the p44/p42 
extracellular signal-regulated kinases (ERK-1/2) of mitogen-activated protein kinases 
(MAPK). Activation of ERK-1/2 results in downstream cytoplasmic phospholipase A2 
(cPLA2) activity (37, 41), which is necessary for the production of arachidonic acid. 
Arachidonic acid acts as the precursor of prostaglandins (e.g., PGE2) and leukotrienes 
(42, 43), which are expressed in inflammation and mitogenesis (44). cPLA2 is also an 
important target for the anti-inflammatory action of glucocorticoids (45). Experiments 
showed that MIF fully diminished glucocorticoid inhibition of cPLA2 activation. 
In addition, ERK-1/2 activates several other downstream effector proteins that 
are involved in the inflammatory response, such as transcription factors (c-myc, NF-
κB, and Ets) and cytoskeletal proteins mediating membrane activation and 
phagocytosis (46, 47). Of note, the sustained ERK-1/2 activation is also shared by the 
stimuli provided by oncogenic mutations in Ras or by integrin co-ligation (48-50), 
suggesting possible molecular explanations for MIF-induced cell proliferation. 
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1.1.2.6 MIF Counteracts Glucocorticoid Effects 
Surprisingly, Calandra et al. demonstrated that macrophage and T cell MIF 
production was induced by low doses of glucocorticoids (17). Glucocorticoids being 
powerful anti-inflammatory mediators, these results appeared paradoxical and 
difficult to reconcile with the pro-inflammatory properties of MIF. However, MIF 
was subsequently found to override the anti-inflammatory and immunosuppressive 
effects of glucocorticoids. In vitro, MIF reversed glucocorticoid-induced inhibition of 
pro-inflammatory cytokine synthesis of TNFα, IL-1β, IL-6 and IL-8. Likewise, in 
vivo, MIF overrode the protective effects mediated by glucocorticoids in a mouse 
model of lethal endotoxemia (17). On a molecular basis, MIF was shown to suppress 
glucocorticoid-induced expression of anti-inflammatory MAPK phosphatase 1 (MKP-
1) (51, 52). MKP-1 is known to inactivate ERK-1/2, p38 and JNK MAPK activities 
and diminishes cytokine production induced by pro-inflammatory and microbial 
stimuli (51, 52). MIF also inhibits the steroid-induced upregulation of cytosolic IκB, 
an inhibitor of the NF-κB pathway (53). 
 
1.1.2.7 MIF Upregulates TLR4 Expression 
Sentinel cells of the innate immune system (e.g., monocytes/macrophages, dendritic 
cells, natural killer cells and granulocytes) possess toll-like receptors (TLR), which 
are activated by constituents of microbial cell walls or pathogen-specific nucleic acids 
(54). Upon activation, they initiate the inflammatory host response against infections 
by stimulating the synthesis and secretion of pro-inflammatory cytokines. In 1999, 
TLR4 was identified as the signal-transducing molecule of the cell-surface receptor 
for LPS, a central component of the outer membrane of Gram-negative bacteria (55). 
Numerous studies have implicated MIF in host response to LPS, suggesting a 
molecular basis by which MIF modulates TLR4 expression. Mitchell et al. reported 
that MIF-receptor binding leads to the phosphorylation of ELK-1 (37), which, as a 
member of the Ets family of transcription factors, is essential for TLR4 gene 
transcription (56). MIF-dependent TLR4 upregulation facilitates the detection of 
endotoxin-containing bacteria and the production of pro-inflammatory cytokines 
essential for a rapid antimicrobial host response. Accordingly, it was demonstrated 
that mif-/- macrophages have a reduced expression level of TLR4. The downregulation 
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of TLR4 in mif-deficient mice leads to a hyporesponsiveness towards LPS resulting in 
a reduced production of TNFα, IL-1β, IL-6 and IL-12 (57). 
 
1.1.2.8 Apoptosis 
Apoptosis is a physiological cell death program. Its tight regulation is critical for host 
survival as abnormalities contribute to a variety of human disease (e.g., ischemic 
damage due to hypertrophy, which facilitates apoptosis in cardiomyocytes, or cancer 
due to uncontrolled cell proliferation) (58, 59). Cells undergoing apoptosis show 
specific morphologic characteristics and differ from cells suffering from necrosis, in 
which the cellular debris can damage the organism. Initiation of apoptosis occurs 
through multiple independent pathways that derive either from triggering events 
outside the cell or within the cell (60) (Figure 2). Of note, NO generation in response 
to a cytokine induced NO-synthase or by NO donors stimulates the expression of the 
tumor suppressor gene p53 in macrophages (61). In turn, p53 accumulation in the 
cytoplasm has a key role in inducing apoptosis, in the maintenance of genomic 
stability, and in the suppression of transformation and tumorigenesis. Mutations in 
p53 have been shown to be the most common genetic alteration in human tumors 
(62). 
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Figure 2: Apoptosis signaling mediated by TNFR, Fas, or mitochondria. Extrinsic initiation of 
apoptosis by activation of TNFR1 (A) or Fas (B) results in the recruitment of adaptor proteins (e.g., 
TRADD, FADD) through interaction with DD. Caspase-8 is activated subsequently. Intrinsic apoptosis 
(C) signaling leads to cytochrome c release from mitochondria, resulting in caspase-9 activation. 
Interactions with anti-apoptotic (e.g., Bcl-2) or pro-apoptotic (e.g., p53) factors are shown. The 
activation of caspase-8 or caspase-9 leads to the activation of the caspase-cascade and, thus, to 
apoptosis. The initiation of the NF-κB signal transduction pathway promotes the transcription of IAPs, 
as well as pro-inflammatory cytokines. IAPs block different caspases; yet, their precise functions are 
not fully determined. Abbreviations: TNFR1, TNF receptor-1; TRADD, TNFR1 associated death 
domain protein; FADD, Fas associated death domain protein; DD, death domain; Bcl-2, B-cell 
lymphoma 2; IAP, inhibitor of apoptosis. Figure modified from (60). 
 
1.1.2.8.1 MIF Suppresses p53 Activity 
When activated (e.g., through LPS-TLR4 interaction), macrophages release NO and 
other oxide radicals at sites of inflammation (63). Multiple target interactions, e.g., 
with protein thiol groups, or direct DNA damage with various NO oxidation products 
serving as the destructive species, have been implicated in NO-mediated cytotoxicity 
used to kill invading organisms (64). However, NO can also induce apoptosis in 
macrophages, limiting their inflammatory activities and lifespan, and therefore the 
inflammatory response over time. In fact, the LPS-induced apoptotic response in 
macrophages has been shown to require the production of NO, the intracellular 
accumulation of the tumor suppressor gene product p53, and activation of a caspase-
dependent cytolytic pathway (65-68). 
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In 1999, Hudson et al. identified MIF as a negative regulator of p53 activity 
(62). Three years later, it was demonstrated that MIF sustains macrophage survival by 
suppressing activation-induced, p53-dependent apoptosis (69). In a model of NO-
induced apoptosis, MIF was shown to prevent p53 accumulation in the cytoplasm. 
The inhibition of p53 activity by MIF requires serial activation of ERK-1/2, cPLA2 
and COX-2. Consistent with these findings, LPS-challenge in mif-deficient mice 
results in severely impaired macrophage viability, decreased pro-inflammatory 
function, and increased apoptotic levels when compared to wild-type macrophages. 
 
1.1.2.8.2 MIF Signaling via Akt 
Binding of MIF to the CD74 receptor results in activation of Src kinase and, thus, 
initiates the phosphoinositide-3-kinase (PI3K)/Akt signaling pathway. Both 
exogenous recombinant MIF and autocrine MIF action lead to Akt activation and 
phosphorylation of the pro-apoptotic proteins BAD and Foxo3a (70). BAD 
phosphorylation impairs its inhibitory action on anti-apoptotic Bcl-2 and protects cells 
from the deleterious effects of apoptotic stimuli. Moreover, phosphorylation of BAD 
attenuates death pathway signaling by raising the threshold at which mitochondria 
release cytochrome c to induce cell death (71). 
Another mechanism associated with the ability of Akt to prevent apoptosis is 
its role in activating NF-κB. Akt stimulates the IκK complex to phosphorylate the 
NF-κB-inhibitory protein IκB. Thus, with the degradation of IκB, the antiapoptotic 
transcription factor NF-κB is freed to enter the nucleus where is up-regulates the 
expression of specific genes involved in immune response, cell survival and 
proliferation (72). Taken together, these data suggest that MIF’s pro-inflammatory 
actions may be due to its unique ability to affect growth regulation, apoptosis, and cell 
cycle control of host immune cells. 
 
1.1.2.9 MIF Affects Cell Viability and Proliferation 
Apoptosis is crucial for host survival because the timely removal of activated immune 
cells is an important mechanism for resolving inflammation and immune responses. 
As MIF suppresses apoptosis, this effect allows for enhanced macrophage survival, 
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increased TNFα, IL-1β, and PGE2 production, and therefore a sustained pro-
inflammatory response (69). Mitchell et al. showed that endotoxin administration to 
mif-/- mice results in decreased macrophage viability, decreased pro-inflammatory 
function, and increased apoptosis when compared with wild-type controls (18, 69). 
Consistent with these findings, inhibition of p53 in endotoxin-treated, MIF-deficient 
macrophages suppresses enhanced apoptosis and restores pro-inflammatory function. 
Mounting evidence suggests that inflammation is closely associated with many 
types of cancer by promoting an in vivo microenvironment which favors tumor 
growths and metastasis (73). In 1997, Weber et al. reported that sustained activation 
of ERK-1 is required for cyclin D1 expression, which controls the transitions between 
successive phases of the cell cycle (74). As MIF has been shown to cause both 
transient and sustained activation of ERK (37), this provides evidence for MIF 
involvement in promoting cell cycle progression, and thus leading to cell 
proliferation. However, in 2000, MIF was identified to co-localize and specifically 
interact with the intracellular protein c-Jun-activation domain-binding protein-1 
(JAB1) (75). JAB1 promotes degradation of the cyclin-dependent kinase inhibitor 
p27Kip1, activates c-Jun amino-terminal kinase (JNK) activity and enhances 
transcription of AP-1, a transcription factor implicated in cell growth, transformation 
and cell death. MIF was reported to inhibit these effects and also to antagonize JAB1-
dependent cell cycle regulation by increasing p27Kip1 expression through its 
stabilization. Taken together, MIF’s effect on macrophage viability and survival 
provides a mechanism to explain its critical pro-inflammatory action in conditions 
such as e.g., sepsis or tumorigenesis. 
 
1.1.3 MIF in Disease Pathology 
1.1.3.1 Sepsis 
Sepsis is an increasingly common cause of morbidity and mortality, particularly in 
elderly, immunocompromised and critically ill patients. While its mortality rate has 
decreased during the past decades, it remains high at between 20% to 40% (76). 
Sepsis and its sequelae have been reported to be the most common cause of death in 
the nonsurgical intensive care units of the developed world (77). The term sepsis 
implies a systemic inflammatory response syndrome (SIRS) (Table 1) that arises from 
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infection (78). Severe sepsis is defined as confirmed sepsis with evidence of end-
organ dysfunction such as altered mental status, episode of hypotension, elevated 
creatinine, or disseminated intravascular coagulopathy. It may lead to multiple organ 
dysfunction syndrome (MODS) involving two or more organ systems or septic shock, 
both severely critical medical conditions. Septic shock is defined as persistent 
hypotension despite adequate fluid resuscitation or tissue hypoperfusion manifested 
by a lactate greater than 4 mg/dl. 
More recent studies of the pathophysiology of sepsis revealed a misbalance 
between pro-inflammatory reactions (designed to kill invading pathogens, but at the 
same time responsible for tissue damage) and anti-inflammatory responses (designed 
to limit excessive inflammation, but at the same time making the host more vulnerable 
for secondary infections) (79). 
 
Table 1: Definition of systemic inflammatory response syndrome (SIRS). SIRS is defined as a 
systemic inflammatory response to a variety of severe clinical insults resulting in distinct medical 
conditions. Documented or suspected infection plus conformed SIRS diagnosis criteria is termed 
sepsis. Table adapted from (80). 
Systemic inflammatory response syndrome (SIRS). 
Defined by the presence of two or more of the following conditions: 
(1) Temperature >38 °C or <36 °C 
(2) Heart rate >90 bpm 
(3) Respiratory rate >20 bpm (tachypnea), or PaCO2 <32 mmHg 
(hyperventilation) 
(4) White blood cell count >12,000 /mm3, <4,000 /mm3, or >10 % immature 
neutrophils (“bands”) 
 
1.1.3.1.1 MIF Potentiates Endotoxemia 
The administration of lipopolysaccharide (LPS) is generally used to create an in vitro 
or a mouse model of spontaneous sepsis/endotoxemia, which mimics early 
biochemical, metabolic, hematologic, and cardiovascular septic responses. MIF is 
rapidly released from immune and pituitary cells after stimulation with LPS, the main 
virulence factor in the cell wall of gram-negative bacteria (11, 13, 30). Experimental 
endotoxemia in mice caused a rapid increase in MIF serum levels, peaking 8 – 20 
hours after LPS challenge. Concurrent intraperitoneal injection of recombinant MIF 
protein and LPS resulted in a marked increase in mice mortality. Conversely, pre-
treatment with neutralizing anti-MIF antibodies, the small molecule MIF inhibitor 
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ISO-1 (81), or deletion of the mif gene (18) reduced pro-inflammatory cytokine 
production and increased the survival rate of mice compared to the control group. 
These results are consistent with models of E. coli injection in the peritoneum or cecal 
ligation and puncture (CLP) (82). An anti-MIF antibody also protected mice from 
lethal peritonitis, even when treatment was started up to 8 hours after CLP. Likewise, 
neutralization of MIF activity reduced lung and liver injury and increased survival in 
models of LPS-induced organ injury, such as acute pancreatitis, or acute hepatic 
failure (83, 84). Finally, MIF was established as an important mediator of LPS-
induced myocardial dysfunction (85). LPS caused MIF release from cardiomyocytes 
into the systemic circulation, whereas anti-MIF antibodies reversed LPS-induced 
cardiac dysfunction. 
Of note, Pollak et al. investigated the role of MIF in susceptibility to bacterial 
superinfection initiated 48 hours after CLP-induced sublethal peritonitis (86). They 
reported that neutralization of endogenous MIF increased mortality in response to 
Salmonella typhimurium, Pseudomonas aeruginosa, or Leishmania monocytogenes 
superinfection, whereas treatment with recombinant human MIF increased survival. 
These findings suggest that MIF modulates immune responses with a positive effect 
on immune-suppressed animals by reenabling them to react adequately to a secondary 
bacterial challenge. 
 
1.1.3.1.2 Serum MIF Levels Increase in Sepsis 
Consistent with the concept established in animal models of septic shock, serum MIF 
concentrations of patients suffering from sepsis were significantly higher compared to 
healthy individuals (median MIF concentrations of 111 ng/ml versus 6.3 ng/ml) (87). 
MIF levels also correlated with the outcome of patients with septic shock as MIF 
concentrations were measured to be significantly higher in non-survivors than in 
survivors and remained elevated for several days (88). A recent study suggested MIF 
as an early predictor for survival in septic patients (89). Thus, were anti-MIF 
therapeutic strategies to become available in the future, they would have a broad time 
window of administration and might potentially increase the survival of sepsis.  
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1.1.3.2 ARDS and Asthma 
MIF has been identified as a major regulator in both acute and chronic inflammation. 
Over time and still to date, MIF involvement in the pathology of an increasing 
number of diseases has been discovered. Lai et al. measured enhanced MIF protein 
expression in alveolar capillary endothelium and infiltrating macrophages derived 
from lung tissues of acute respiratory distress syndrome (ARDS) patients in 
comparison to healthy controls (90). In asthma, a chronic allergic pulmonary disease, 
similar results were observed. Eosinophils of atopic patients comprised intracellular 
pools with higher MIF amounts, which were secreted in response to inflammatory 
stimulation in vitro. Alveolar fluids derived from the lungs of stable asthmatic 
patients contained elevated MIF levels (28). Moreover, neutralization of MIF 
abrogated the development of airway hyperresponsiveness and airway inflammation 
in sensitized mice (91). In 2005, genetic analysis of the MIF genotype was performed 
in patients with mild, moderate, or severe asthma (22). Mizue et al. observed a 
significant association between mild asthma and the low expression, 5-CATT MIF 
allele. The human MIF gene comprises a CATT-tetranucleotide repeat polymorphism 
that functionally affects the activity of the MIF promoter (24). It is repeated between 
5-8 times while a high number of repeats results in an increase in MIF promoter 
activity. The 5-CATT MIF promoter polymorphism has also been correlated with low 
disease severity in rheumatoid arthritis patients. 
 
1.1.3.3 Rheumatoid Arthritis 
The first evidence of a role for MIF in rheumatoid arthritis (RA) was provided in 
1997 (92). In a mouse model of collagen type-II induced arthritis, neutralization of 
MIF led to delayed onset and lowered frequency of RA. Treatment with neutralizing 
anti-MIF antibodies in adjuvant-induced arthritis and antigen-induced arthritis were in 
accord with these results (93, 94). In RA patients, high amounts of MIF have been 
detected in synovial fluid and tissues, most notably in fibroblast-like synoviocytes 
(FLS), macrophages, and T-lymphocytes, which might be the major source of MIF 
detected in the synovial fluid (95, 96). In 2004, Gregory et al. determined that 
leukocyte migration into the joint space was significantly reduced in mif-deficient 
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mice, indicating that MIF is associated with disease activity and preceding structural 
damage in the joint (97). 
 
1.1.3.4 Atherosclerosis 
Furthermore, MIF has been implicated in atherosclerotic plaque development. First 
evidence for an involvement of MIF in atherogenesis was unveiled in 
hypercholesterolemic rabbits in 2000. Lin et al. reported that MIF was strongly 
overexpressed in vascular endothelial cells in the early fatty-streak and advanced 
lesion stages of atherosclerosis, and in monocytes adhering to the endothelial cells 
(98). Interestingly, this observation was diminished in smooth muscle cells (SMC) in 
the media of vessels, foam cells and macrophages of advanced plaques, suggesting 
predominant MIF involvement in early lesion development. In 2002, increased MIF 
protein expression was reported in human atheroma lesions, which was accompanied 
by an increase in disease progression. MIF expression in human umbilical vein 
endothelial cells (HUVEC) was upregulated after stimulation with oxidized low-
density lipoprotein (LDL) and macrophages secreted enhanced levels of MIF upon 
LDL stimulation (99). In a mouse model of spontaneous atherogenesis, treatment with 
anti-MIF antibody led to a reduction of intimal macrophages, and circulating 
inflammatory mediators, such as fibrinogen, MIF and IL-6, compared to controls. 
Accordingly, proteins involved in leukocyte recruitment were reduced upon MIF 
blockade (100). More recent studies revealed that MIF supports leukocyte recruitment 
to sites of inflammation by upregulation of intercellular adhesion molecule-1 (ICAM-
1) on endothelial cells, and through interaction with the chemokine receptors CXCR2 
and CXCR4 (20, 101). Lately, MIF has been proposed to serve as a link between 
rheumatoid arthritis and atherosclerosis (102), as inflammatory processes in the vessel 
wall are widely acknowledged to give rise to atherosclerosis (103). 
 
1.1.4 Structure, Enzymatic Activities and Inhibitors 
1.1.4.1 Three-Dimensional Structure 
Human MIF is a 114-amino-acid non-glycosylated protein of 12,476.3 Da that shows 
approximately 90% sequence homology in all mammalian species studied so far 
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(104). Homologues of mammalian MIF have been found not only in mammals but 
also in both jawless and jawed fish, ticks, the nematodes C. elegans and B. malayi, 
cyanobacteria, and plants such as Arabidopsis thaliana (105-109). 
In 1996, crystallographic studies of human and rat MIF showed that MIF is a 
homotrimer (110-112). Each monomer contains two antiparallel α-helices and six β-
strands; four of these strands form a β-sheet (Figure 3). Performing NMR studies, 
Mühlhahn et al. suggested that the protein could be dimeric in solution (113), whereas 
cross-linking analysis data even indicated that physiological MIF solutions contain a 
mixture of monomers, dimers, and trimers (114). The precise determination of the 
physiological multimerization state of MIF is still not answered to satisfaction. 
MIF’s three-dimensional oligomeric structure led to the definition of a new 
protein class named the MIF/tautomerase superfamily. Structurally similar to MIF, 
other family members are D-dopachrome tautomerase (D-DT) and the bacterial 
enzymes 5-carbodymethyl-2-hydroxymuconate isomerase (CHMI) and 4-
oxalocrotonate tautomerase (4-OT) (115). 
 
 
Figure 3: The three-dimensional structure of MIF. Left: Human MIF monomer. Right: Human MIF 
trimer. Each monomer contains two antiparallel α-helices that pack against a four-stranded β-sheet. 
Additionally, each monomer has two β-strands that interact with the β-sheets of adjacent subunits to 
form the interface between monomers. The three β-sheets are arranged to form a barrel containing a 
solvent-accessible channel that runs through the center of the protein (110). Structures taken from 
(116). 
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1.1.4.2 Enzymatic Activities 
To date, two enzymatic activities have been reported for MIF. First, MIF exhibits 
thiol-protein oxidoreductase (TPOR) activity, which is mediated by a Cys57-Ala-Leu-
Cys60 (CALC) sequence motif (117). Although not reconcilable with the static 
structure of MIF found in crystallographic studies, the cysteines are reported to form a 
reversible, intramolecular disulfide bridge, which is the catalytic center of MIF (118, 
119). Some MIF-mediated immune processes, such as the activation of macrophages, 
are due to this cysteine-mediated redox mechanism. The CALC motif is structurally 
sensitive because mutations, especially at Cys60, result in dramatic changes in the 
folding of MIF. It also lies within the JAB1-binding site (120) that many, but not all, 
vertebrate homologues possess (106). 
Additionally, MIF has been identified as an enzyme that catalyzes the 
tautomerization of model substrates such as D-dopachrome and p-
hydroxyphenylpyruvate (HPP) (121) (Figure 4A and B). To date, the physiological 
substrate for the tautomerase activity is still unknown. However, the tautomerase 
activity requires the trimerization of MIF, because the active site is formed between 
subunits of the trimeric human MIF molecule as described for the substrate HPP 
(122). HPP interacts with Pro1, Lys32, and Ile64 from one subunit and Tyr95 and 
Asn97 from an adjacent subunit (Figure 4C). MIF shares this enzymatic activity with 
all members of the MIF/tautomerase superfamily (D-DT, CHMI, 4-OT). Although 
there is no sequence homology between MIF, CHMI and 4-OT, the proteins share an 
N-terminal proline as the catalytic base for the tautomerase activity (122). 
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Figure 4: The tautomerase reaction of MIF. A) MIF converts D-dopachrome to 5,6-dihydroxyindol-
2-carboxylic acid. B) MIF also catalyzes the keto-enol isomerization of p-hydroxyphenylpyruvate and 
phenylpyruvate. Structures modified from (116). C) Interactions of MIF with the substrate HPP. 
Structure modified from (122). 
 
1.1.4.3 Small Molecule Inhibitors 
Pro-inflammatory function studies of MIF have shown a direct association between 
the catalytic site surrounding Pro1 and MIF’s pro-inflammatory actions. Mutational 
analysis of the catalytic site around Pro1 led to the conclusion that it is involved in the 
counter-regulation of glucocorticoids (123), neutrophil priming (124) and the 
upregulation of metalloproteinases-1 and -3 in rheumatoid arthritis synovial 
fibroblasts (125). Therefore, it was reasoned that molecules that target this site could 
be useful to inhibit MIF’s actions in vitro and in vivo. Prototypic small molecules 
were characterized as catalytic inhibitors of MIF’s enzymatic activity by binding to 
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the protein’s amino-terminal tautomerase region. Prominent inhibitors are N-acetyl-p-
benzo-quinoneimine (NAPQI) (126), (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-
isoxazole acetic acid methyl ester (ISO-1) (123), and 4-iodo-6-phenylpyrimidine (4-
IPP) (127) (Figure 5). 
The reaction between the iminoquinone metabolite of acetaminophen NAPQI 
and MIF is covalent and produces a NAPQI-modified MIF species with inhibited 
tautomerase activity, diminished cell-binding ability and decreased 
immunorecognition (126). ISO-1 binds reversibly to MIF and not only inhibits MIF’s 
tautomerase activity, but also its glucocorticoid counter-regulation activity, MIF-
induced production of TNFα, PGE2 and COX-2 (123), and protects against death in 
an in vivo murine model of endotoxic shock (81). Using computational virtual 
screening, 4-IPP was identified as a suicide substrate for MIF, causing the covalent 
modification of Pro1. Functional studies indicated that this compound is 
approximately 5-10 times more potent than ISO-1 in blocking MIF-dependent 
catalysis, cell migration and anchorage-independent growth in vitro (123). Further 
differences in the inhibitory potencies of these small molecule inhibitors are evident 
when comparing the half maximal inhibitory concentration (IC50) determined by the 
D-dopachrome tautomerase assay; ISO-1 has an IC50 of ~50 µM, NAPQI of ~40 µM, 
and 4-IPP of ~5 µM (116). 
In 2011, Al-Abed et al. reported on the first potential endogenous MIF 
antagonist, the thyroid hormone thyroxine (T4) (128). The authors suggested that T4 
might influence MIF-mediated inflammatory responses (e.g. survival in mice with 
severe sepsis) via inhibition of its amino-terminal tautomerase region.  
 
 
Figure 5: Small molecule MIF inhibitors. Left: NAPQI. Middle: ISO-1. Right: 4-IPP. Structures 
modified from (116). 
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1.2 D-Dopachrome Tautomerase 
1.2.1 Discovery in Melanoma Cells 
In 1990, a new protein was purified from mouse melanocytes during an investigation 
of the regulation of mammalian melanogenesis (129). It was referred to as 
dopachrome tautomerase according to its tautomerase activity on dopachrome. Aroca 
et al. reported that dopachrome tautomerase increases the amount of melanin formed 
from L-tyrosine by melanoma tyrosinase. Subsequently, two membrane-bound L-
isomers of dopachrome tautomerase, tyrosinase-related protein-1 and -2 (TRP-1, 
TRP-2), were defined in melanin forming cells (130, 131). Both enzymes catalyze the 
isomerization of L-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA). 
In 1993, Odh et al. reported the purification of an enzyme specific for the 
tautomerization of D-dopachrome, which they named D-dopachrome tautomerase 
(132). The enzymatic activity of D-DT was described in the liver, kidney, brain, 
spleen and heart of a male rat as well as in the cytoplasm of human melanoma cells, 
liver cells, and, later, in blood cells (133). 
 
1.2.2 A Structural Homologue of MIF 
D-DT shares very little similarity with any of the L-dopachrome tautomerases. D-DT 
has been shown to be present in the cytoplasm instead of being membrane-bound 
(132). Also, the monomer has a low molecular weight (approximately 12 kDa) and a 
unique amino acid sequence that is not homologues with that of tyrosinase. In 1994, 
the molecular cloning of D-DT has shown only marginal amino acid sequence 
homology with either one of the L-dopachrome tautomerases (TRP-1 or TRP-2) 
(134). However, Merk et al. reported 34% identities in the amino acid sequence 
between human MIF and D-DT (87). Likewise, their murine homologues share 27% 
identity and 45% homology (Figure 6). Both proteins are of similar size, about 12 
kDa, and Pro1, the catalytic base of the tautomerase activity in MIF, as well as the 
active site residues Lys32 and Ile64 are conserved in D-DT. Of note, no CALC-motif 
can be found in D-DT, which is associated with the TPOR activity of MIF (117). 
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Figure 6: Sequence alignment of murine MIF with murine D-DT. Murine MIF and murine D-DT 
share 27% sequence identity. A black background marks invariant residues between MIF and D-DT; a 
box signalizes similar residues. Elements of the secondary structure of murine MIF are shown; α 
indicates α-helix, whereas β stands for a β-strand of β-sheet, η for a short α-helix and Τ for turns. 
Structure modified from (116). 
 
In 1999, Sugimoto et al. determined the crystal structure of human D-DT (135) 
(Figure 7). With respect to the overall three-dimensional (3D) structure of D-DT, it is 
noteworthy that D-DT shares structural homology with MIF. D-DT’s overall 
homotrimeric folding and its subunit topology are almost identical of human MIF. 
Each monomer possesses two βαβ motifs and similar trimeric packing by inter-
subunit β-sheets compared to MIF. 
 
 
Figure 7: Human D-dopachrome tautomerase. Left: human D-DT monomer. Right: human D-DT 
trimer. Structures taken from (116). 
 
1.2.3 Tautomerase Activity 
D-dopachrome and p-hydroxyphenylpyruvate have been found to serve as substrates 
for enzymatic activity of both enzymes, MIF and D-DT (132, 136, 137). In contrast to 
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MIF, which converts D-dopachrome to DHICA, D-DT decarboxylases D-dopachrome 
to 5,6-dihydroxyindole (DHI) (Figure 8). 
 
 
Figure 8: D-dopachrome tautomerization of D-DT and MIF. Left: D-DT catalyzes D-dopachrome 
to DHI. Right: MIF converts D-dopachrome to DHICA. Structures modified from (135). 
 
1.2.4 D-DT in Disease Pathology 
To date, there is very little knowledge about the physiological functions and 
mechanisms of action of D-DT. It is expressed in a large amount in the liver, and to 
lesser extent in other organs, including the heart, lung and pancreas (138). A first 
analysis of D-DT expression in murine tissue reveals constitutive and appreciable D-
DT levels in several organs with the highest concentration in testis (87). 
 
1.2.4.1 Acute Inflammation 
In 2003, Sonesson et al. investigated the correlation between UVB-induced skin 
inflammation and the activity of D-DT in blister fluid (139). In response to UVB 
light, D-DT activity increased 2-fold, and so did the activity of MIF. These findings 
provided first evidence of D-DT involvement in inflammation while its co-variation 
with MIF strengthens this observation. Accordingly, it was reported that D-DT, like 
MIF, was released from macrophages in response to the pro-inflammatory stimulus 
LPS (116). The release pattern of both proteins exhibited a bell-shaped curve, that in 
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the case of D-DT peaked at 16 h after LPS stimulation (116). However, cultured 
macrophages produced 20-fold more MIF than D-DT in response to LPS stimulation. 
 
1.2.4.2 Neoplasm 
In 2008, Coleman et al. suggested a biological role for D-DT in non-small cell lung 
carcinomas (NSCLC) (140). The authors showed that the expression of pro-
angiogenic factors, such as CXCL8 and vascular endothelial growth factor (VEGF), 
in NSCLC cells was strongly reliant upon both the individual and cooperative 
activities of MIF and D-DT. Depletion of MIF and/or D-DT reduced the basal 
secretion of these two proteins, indicating a tumor-supportive action of D-DT. Tumor-
derived growth factors (such as CXCL8 and VEGF) stimulate angiogenesis from 
surrounding capillaries to support tumor growth and are crucial for tumor progression. 
MIF and D-DT regulated the CXCL8 transcription via a signaling pathway that 
appeared to involve JNK, c-JUN and AP-1. Furthermore, the MIF receptor, CD74, 
was shown to be necessary for MIF- and D-DT-induced JNK activation and CXCL8 
expression. 
More recently, D-DT was shown to contribute to colorectal cancer disease 
progression (141). Xin et al. observed that D-DT increases COX-2 expression in 
colorectal adenocarcinoma cell lines through β-catenin stabilization, and activation of 
c-jun-N-terminal kinase and Jab1/CSN5. As MIF-dependent COX-2 expression has 
been linked to neoplastic disease progression, these findings suggest a regulatory role 
for D-DT in cancer pathogenesis. 
 
1.2.4.3 Liver Disease 
Proteomic studies of rat liver conducted in 2009 suggested that D-DT is a key protein 
in liver damage, protection and regeneration (142). A twelve-fold increase in D-DT 
protein level was measured in rat hepatocytes 24 h after carbon tetrachloride (CCl4)-
induced liver damage compared to control. Protein levels of the antioxidant melanin 
were also increased in hepatocytes of CCl4-treated rats. As D-DT has been reported to 
be involved in the biosynthesis of melanin (132), Hiyoshi et al. proposed that 
increased D-DT levels in response to liver damage could accelerate melanin 
biosynthesis and therefore protect the liver from oxidative stress. Accordingly, D-DT 
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has been identified as an urinary biomarker of hepatic fibrosis in a rat model of CCl4-
induced hepatic fibrosis (143). 
 
1.3 Specific Aim of this Thesis 
The 3D structures of MIF and D-DT are highly conserved. Both proteins possess a 
tautomerase active site that has its catalytic base in the amino-terminal Pro1. Thus, 
both proteins belong to the MIF/tautomerase superfamily. However, while the 
knowledge of MIF’s prominent role as a regulator of the innate and adaptive 
immunity has grown tremendously over the last decades, very little is known about 
the physiological role of D-DT. As D-DT shows striking structural homology to MIF, 
it might be suspected that approaches of studying MIF’s actions might not be 
complete without considering D-DT’s possible role in disease development. 
Therefore, detailed functional studies need to be conducted to elucidate whether D-
DT exerts similar biological activities to MIF or whether it acts as a cross-regulator 
or possibly antagonist of MIF. Both scenarios are well documented in immunology. 
The aim of this thesis was to investigate D-DT’s enzymatic and biological 
functions to validate previous studies, and to further develop our understanding of D-
DT. I first wished to investigate D-DT’s influence on cell survival by means of an 
apoptosis and vitality assay. Second, I wanted to address D-DT’s tautomerase activity 
on the model substrate HPP in comparison to MIF. Also, I planned to probe the 
effects of catalytic MIF inhibitors on D-DT. Third, the potential effects of an 
immunoneutralization of D-DT in a murine model of endotoxic shock were to be 
studied. 
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2 MATERIAL AND METHODS 
2.1 Cell Lines, Bacteria and Plasmids 
2.1.1 Cell Lines 
Description Cell type Morphology 
COS-7 African green monkey kidney cells Fibroblast, adherent 
RAW 264.7 Murine ascites leukemia cells Macrophage/monocyte, 
adherent 
2.1.2 Bacteria 
Strain Genotype Origin 
E. coli TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen, 
Carlsbad, CA 
2.1.3 Plasmids 
Plasmid Insert Resistance/Promotor Origin 
pcDNA 3.1 hD-DT Amp/ T7 this work 
pcDNA 3.1 mD-DT Amp/ T7 this work 
pcDNA 3.1 mMIF Amp/ T7 Bucala lab 
 
2.2 Equipment, Consumables and Chemicals 
2.2.1 Equipment 
Equipment Manufacturer 
Amaxa nucleofector Amaxa, Gaithersburg, MD 
Analytical balance Acculab, Columbia, MD 
Beckman Alegra6 centrifuge Beckman, Fullerton, CA 
Bright-Line hemacytometer set Hausser Scientific, Horsham, PA 
Centrifuge 5417 R Eppendorf Eppendorf, Westbury, NY 
Centrifuge 5417 R Eppendorf Eppendorf, Wesseling-Berzdorf, Germany 
CO2 incubator Heracell Thermo Scientific, Waltham, MA 
CO2 incubator Heracell Heraeus Instruments, Hanau, Germany 
Electrophoresis Power Supply BioRad, Hercules, CA 
Heat block thermo mixer comfort Eppendorf, Westbury, NY 
HERA-Safe sterile bench Heraeus Instruments, Hanau, Germany 
HERA-Safe sterile bench Thermo Scientific, Waltham, MA 
Light microscope Carl Zeiss, Thornwood, NY 
Light microscope Olympus CK40 Olympus Co GmbH, Hamburg, Germany 
LSM510 confocal microscope Carl Zeiss, Thornwood, NY 
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ND-1000 Spectrophotometer NanoDrop, Wilmington, DE 
NuPAGE/Xcell II Blot Module Invitrogen, Carlsbad, CA 
NuPAGE/Xcell SureLock Invitrogen, Carlsbad, CA 
PTC-100 PCR BioRad, Hercules, CA 
Sorvall Centrifuge Thermo Scientific, Waltham, MA 
SpectraMax Plus Molecular Devices, Sunnyvale, CA 
2.2.2 Consumables 
Consumables Manufacturer 
BioMax MR Film Kodak, Rochester, NY 
BioMax MS Film Kodak, Rochester, NY 
Blotting paper Whatman, Clifton, NJ 
Cell culture equipment BD Falcon, Bedford, MA 
Greiner, Frickenhausen, Germany 
Cell scrapers BD Falcon, Bedford, MA 
Centricon Amicon Bioseparations 
Culture Slides BD Falcon, Bedford, MA 
Eppendorf tubes Eppendorf, Westbury, NY 
Eppendorf GmbH, Wesseling-Berzdorf, 
Germany 
NuPAGE 4-12% Bis-Tris-Gels Invitrogen, Carlsbad, CA 
Polypropylene tubes BD Falcon, Bedford, MA 
PVDF membrane Millipore, Bedford, MS 
Thin wall PCR tubes BioRad, Hercules, CA 
2.2.3 Chemicals 
Chemicals Manufacturer 
β-Mercaptoethanol Sigma, St. Louis, MO 
100 bp DNA ladder Invitrogen, Carlsbad, CA 
4-HPP Sigma, St. Louis, MO 
Acetonitrile J.T. Baker, Phillipsburg, NJ 
Agarose Sigma, St. Louis, MO 
Bradford Reagent BioRad, Hercules, CA 
Bromophenol Blue sodium salt Sigma, St. Louis, MO 
BSA American Bioanalytical, Natick, MA 
Dimethylsulfoxide Sigma, St. Louis, MO 
Dithiothreitol (DTT) Sigma, St. Louis, MO 
DMEM Invitrogen, Carlsbad, CA 
Invitrogen, Eggenstein, Germany 
Dry milk powder BioRad, Hercules, CA 
EDTA American Bioanalytical, Natick, MA 
ELC substrate Pierce, Rockfolrd, IL 
FBS Invitrogen, Carlsbad, CA 
Invitrogen, Eggenstein, Germany 
Formaldehyde American Bioanalytical, Natick, MA 
Glycerol Sigma, St. Louis, MO 
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Goat serum Sigma, St. Louis, MO 
Imidazole Sigma, St. Louis, MO 
LB Agar Ampicillin-100 Plates Sigma, St. Louis, MO 
Lipofectamine 2000 Invitrogen, Carlsbad, CA 
Lipopolysaccharide 0111:B4 Sigma, St. Louis, MO 
Sigma, Munich, Germany 
Luria Broth medium Invitrogen, Carlsbad, CA 
Methanol Fisher Scientific, Pittsburgh, PA 
Na3VO4 Sigma, St. Louis, MO 
NaCl J.T. Baker, Phillipsburg, NJ 
NaF Sigma, St. Louis, MO 
NuPAGE LDS sample buffer Invitrogen, Carlsbad, CA 
NuPAGE SDS running buffer Invitrogen, Carlsbad, CA 
NuPAGE transfer buffer Invitrogen, Carlsbad, CA 
Opti-MEM I Reduced-Serum 
Medium 
Invitrogen, Carlsbad, CA 
PCR SuperMix Invitrogen, Carlsbad, CA 
Penicillin/Streptomycin Invitrogen, Carlsbad, CA 
Phosphate buffered saline Invitrogen, Carlsbad, CA 
Protein Free Blocking buffer Thermo Scientific, Waltham, MA 
Protein G Sepharose Sigma, St. Louis, MO 
SeaBlue Plus2 Invitrogen, Carlsbad, CA 
SOC medium Invitrogen, Carlsbad, CA 
Sodiumdodecylsulfate Sigma, St. Louis, MO 
Streptavidin-HRP Promega, Madison, WI 
Stripping buffer Thermo Scientific, Waltham, MA 
Superblock Pierce, Rockfolrd, IL 
TAE buffer Invitrogen, Carlsbad, CA 
TMB substrate system Dako, Carpinteria, CA 
Tris American Bioanalytical, Natick, MA 
Triton-X-100 Sigma, St. Louis, MO 
Trypsin/EDTA Invitrogen, Carlsbad, CA 
Tween-20 Sigma, St. Louis, MO 
2.2.4 Multi-Component Systems 
Kits Manufacturer 
Cell Death Detection ELISA Plus Roche, Indianapolis, IN 
GeneClean III  MP Biomedicals, Solon, OH 
MTT Cell Proliferation Assay Kit Cayman Chemical, Ann Arbor, MI 
Nucleofector Kit V for RAW 264.7 Lonza, Allendale, NJ 
pcDNA 3.1/V5-His TOPO TA Expression Kit Invitrogen, Carlsbad, CA 
QlAprep MiniPrep Qiagen, Valencia, CA 
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2.3 Primary and Secondary Antibodies 
2.3.1 Primary Antibodies 
Antigen Species/Type Application* Manufacturer 
β-Actin Mouse IgG1 (monoclonal) WB Sigma, St. Louis, MO 
D-DT Rabbit IgG (polyclonal) WB Bucala lab 
MIF (N20) Goat IgG (polyclonal) WB Santa Cruz 
Biotechnology, Santa 
Cruz, CA 
*WB: Western blot 
2.3.2 Secondary Antibodies 
Description* Species/Type Application** Manufacturer 
Anti-goat HRP Donkey WB Santa Cruz Biotechnology, 
Santa Cruz, CA 
Anti-mouse HRP Horse WB Cell Signaling, Danvers, MA 
Anti-rabbit HRP Goat WB Cell Signaling, Danvers, MA 
*HRP: Horseradish peroxidase 
**WB: Western blot 
 
2.4 PCR Primers 
Description Sequence 
hD-DT-forward 5’-ATGCCGTTCCTGGAGCTG-3’ 
hD-DT-reverse 5’-GGTCATGACTTTTTTATGA-3’ 
mD-DT-forward 5’-ATGCCATTCGTTGAGTTG-3’ 
mD-DT-reverse 5’-GGAACTGTCATGACATTTCTGTGA-3’ 
 
2.5 Media, Buffers and Solutions 
2.5.1 Media 
Complete growth medium for RAW 264.7, COS-7 and 
mouse peritoneal macrophages 
Concentration 
DMEM 90% 
FBS 10% 
Penicillin/streptomycin 1 U/ml 
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Complete growth medium for COS-7 prior to 
transfection 
Concentration 
DMEM 90% 
FBS 10% 
 
Quiescent medium for mouse peritoneal macrophages Concentration 
DMEM low glucose 99.9% 
FBS 0.1% 
Penicillin/streptomycin 1 U/ml 
2.5.2 Buffers and Solutions 
All buffers were prepared with distilled water, if not stated otherwise. 
2.5.2.1 General Buffers 
TBS, pH 7.4 Concentration 
Tris-HCl, pH 7.4 20 mM 
NaCl 150 mM 
 
TBS-T, pH 7.4 Concentration 
TBS (buffer) 
Tween-20 0.05% 
 
RIPA Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 150 mM 
EDTA 2 mM 
Nonident P-40 1% 
Sodium deoxycholate 0.5% 
SDS 0.1% 
Protease inhibitors complex 1x 
2.5.2.2 Agarose Gel Electrophoresis 
Gel buffer Concentration 
TAE (buffer) 
EtBr 0.5% 
 
Running buffer Concentration 
TAE (buffer) 
2.5.2.3 SDS-PAGE and Western Blot 
Running buffer Concentration 
MES running buffer 20x (NuPAGE) 1x 
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Transfer buffer Concentration 
Transfer buffer 20x (NuPAGE) 1x 
Methanol 10% 
 
Blocking buffer Concentration 
TBS-T (buffer) 
Dry milk powder 5% 
 
Washing buffer Concentration 
TBS-T (buffer) 
2.5.2.4 Enzymatic Activity 
HPP buffer, pH 6.0 Concentration 
Sodium acetate, 0.05 M (buffer) 
4-HPP 5 mM 
 
HPP buffer was kept dark at room temperature for 24 h in order for HPP to 
tautomerize into its keto form. It was then stable at 4 °C for two weeks. 
 
Sodium borate buffer, pH 6.2 Concentration 
NaOH (buffer) 
Boric acid 0.5 M 
 
2.6 Molecular Biology Techniques 
2.6.1 Measurement of DNA Concentration 
The concentration and purity of DNA was assessed by photometric analysis using the 
NanoDrop-1000 Spectrophotometer. The absorption of the nucleotides was measured 
at OD260 and OD280, where 1 OD260 value equals 50 µg/ml DNA. The ratio between 
OD260 vs. OD280 assesses the purity of the sample with respect to protein 
contamination. A quotient of 1.8 to 2.0 indicates an uncontaminated sample. 
 
2.6.2 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) is used to amplify DNA fragments resulting in 
thousands to millions of copies of a particular DNA sequence. PCR consists of a 
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series of 20 to 40 repeated temperature changes called cycles; each cycle typically 
consists of three discrete temperature steps: 
 
Table 2: Principle of PCR. 
Step 1 Denaturation Heating the reaction to 95°C causes disruption of the 
hydrogen bonds between complimentary bases, yielding 
single strands of DNA. 
Step 2 Annealing Lowering the reaction temperature to 50-55°C (~5°C lower 
than the Tm of the primers used) allows annealing of the 
primers to the single-stranded DNA template. 
Step 3 Elongation DNA polymerase synthesizes a new DNA strand 
complementary to the DNA template strand by adding 
dNTPs in 5’ to 3’ direction. 
 
Human D-DT (hD-DT) and murine D-DT (mD-DT) cDNA fragments were 
amplified using Taq polymerase, which has its optimum activity temperature at 72°C. 
The reaction mixture was prepared according to the manufacturer’s recommendations. 
The protocol for amplification included: 
 
hD-DT: 
PCR reaction mixture Amount 
PCR SuperMix 45 µl 
hD-DT forward primer, 10 µM 1 µl 
hD-DT reverse primer, 10 µM 1 µl 
hD-DT DNA 2 µl 
H2O 1 µl 
Total 50 µ l 
 
Step Number of cycles Temperature Duration 
1 1 95 °C 5 min 
2 35 95 °C 30 sec 
  55 °C 30 sec 
  72 °C 1 min 
3 1 72 °C 5 min 
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mD-DT: 
PCR reaction mixture Amount 
PCR SuperMix 45 µl 
mD-DT forward primer, 10 µM 1 µl 
mD-DT reverse primer, 10 µM 1 µl 
mD-DT DNA 1 µl 
H2O 2 µl 
Total 50 µ l 
 
Step Number of cycles Temperature Duration 
1 1 95 °C 5 min 
2 35 95 °C 30 sec 
  50 °C 30 sec 
  72 °C 1 min 
3 1 72 °C 5 min 
 
2.6.3 Agarose Gel Electrophoresis 
In order to identify and purify DNA after PCR, DNA was separated according to its 
mass via agarose gel electrophoresis. This was achieved by moving negatively 
charged nucleic acid molecules through a 1% agarose matrix containing ethidium 
bromide (EtBr) with an electric field. Smaller molecules moved faster and migrated 
farther in the gel than bigger ones. EtBr fluoresced under UV light when intercalated 
into DNA and, thus, visualized DNA bands. 
One per cent agarose solution was made in TAE + EtBr buffer and 
microwaved until the agarose was completely dissolved. After cooling down to about 
60 °C, the solution was poured into the gel rack. While continuously cooling down, 
the agarose polymerized and formed a solid gel. hD-DT and mD-DT PCR products 
were prepared at a molar ratio of 1:6 in bromophenol blue loading buffer for agarose 
gel electrophoresis. Fifteen µl of 100 bp DNA ladder and 60 µl of hD-DT and mD-DT 
PCR samples were loaded into agarose gel slots. After covering the gel completely 
with TAE, 100 V was applied for 25 min. DNA bands were visualized under UV 
light. 
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2.6.4 Isolation and Purification of DNA from Agarose Gels 
hD-DT and mD-DT DNA were run on an agarose gel and the desired bands excised 
from the gel with a razor blade. DNA was eluted using GeneClean® III Kit 
containing NaI, New Wash and GLASSMILK®. In the presence of NaI, DNA binds 
to silica beads (GLASSMILK®). After washing off all other proteins, DNA is diluted 
in TE buffer protecting it from degradation. 
The excised DNA/agarose band was weighed and three volumes of NaI 
solution added (0.1 g DNA/agarose equals 100 µl NaI). The tubes were placed in a 50 
°C water bath incubator until the agarose was completely dissolved (approximately 5 
min). Fifteen µl of GLASSMILK® suspension was added. The tubes were inverted 
and incubated at room temperature for 5 min. Then, the DNA/GLASSMILK® 
solution was centrifuged shortly at 14,000 rpm using a Centrifuge 5417 R 
(Eppendorf). The supernatant was removed while the pellet contained the 
DNA/GLASSMILK® complexes. Subsequently, the pellet was washed three times 
with 750 µl of New Wash. Therefore, the pellet was resuspended in New Wash, 
centrifuged shortly and the supernatant discarded. Following the washing step, the 
DNA/GLASSMILK® complexes were eluted into 20 µl of TE buffer by resuspending 
the pellet. The solution was centrifuged at 14,000 rpm for 1 min. The supernatant 
containing TE and the eluted DNA was carefully removed and placed in a new tube. 
 
2.6.5 TOPO Cloning Reaction 
The TOPO® cloning reaction was set up and incubated at room temperature for 30 
min: 
 
TOPO®  cloning reaction Amount 
hD-DT / mD-DT DNA 4 µl 
Salt Solution 1 µl 
TOPO® vector 1 µl 
Total 6 µl 
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2.6.6 Heat-shock Transformation of E. coli 
After thawing an aliquot of competent cells on ice, bacteria were incubated with 2 µl 
of hD-DT / mD-DT TOPO® cloning reagent for 30 min on ice prior to 
transformation. Heat-shock transformation occurred via incubation for 30 s at 42 °C. 
Subsequently, bacteria were kept on ice for two minutes and incubated at 37 °C in 
250 µl of SOC medium for 1 h. Bacteria were plated on LB-agar plates containing 
100 µg/ml ampicillin and incubated o/n at 37 °C. 
 
2.6.7 Colony PCR 
In order to determine whether the hD-DT / mD-DT DNA was inserted into the 
TOPO® vector, colony PCR was performed. The components of the colony PCR 
reaction mixture are listed below, whereas the colony PCR protocol was performed 
according to the PCR amplification protocol (paragraph 2.6.2). 
 
Colony PCR reaction mixture Amount 
PCR SuperMix 45 µl 
hD-DT / mD-DT forward primer, 10 µM 1 µl 
hD-DT / mD-DT reverse primer, 10 µM 1 µl 
Half of an E. coli colony ~ 1 µl 
H2O 2 µl 
Total 50 µ l 
 
2.6.8 Agarose Gel Electrophoresis of Colony PCR Products 
The agarose gel electrophoresis of colony PCR products was performed according to 
the agarose gel electrophoresis protocol (paragraph 2.6.3). 
 
2.6.9 Plasmid Isolation 
E. coli colonies, which have been proven to contain hD-DT or mD-DT DNA in their 
transformed vectors, were grown at 37 °C o/n in 5 ml of LB medium subjoined with 
carbenicillin at a final concentration of 50 µg/ml. The next day, plasmids were 
isolated with the QlAprep MiniPrep according to the manufacturer’s 
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recommendations. Four ml of LB medium containing bacteria were centrifuged at 
3,000 rpm at 4 °C for 10 min (Beckman Alegra6 centrifuge). The supernatant was 
removed, the pelleted bacterial cells resuspended in 250 µl of buffer P1 and 
transferred into a microcentrifuge tube. Then, 250 µl of buffer P2 and 350 µl of buffer 
N3 were added and thoroughly mixed by inverting the tube a few times. The mixture 
was centrifuged at 13,000 rpm at room temperature for 10 min and the supernatant 
pipetted to the QlAprep spin column. Subsequently, it was centrifuged at 10,000 rpm 
at room temperature for 1 min. Washing the QlAprep spin column with 750 µl of 
buffer PE containing ethanol was followed by DNA elution. To do so, the QlAprep 
spin column was placed in a clean microcentrifuge tube, 50 µl of H2O added and 
incubated at room temperature for 1 min. After centrifuging at 13,000 rpm at room 
temperature for 1 min, the flow-through contained the isolated hD-DT / mD-DT 
plasmid. 
 
2.6.10 Glycerol Cryo Stock of Bacteria 
One ml of LB medium containing hD-DT or mD-DT transformed E. coli bacteria 
were pipetted into cryo tubes. Subsequently, 150 µl of 100% Glycerol was added. 
Tubes were vortexed and stored at - 80 °C for further use. 
 
2.6.11 DNA Sequencing 
DNA sequencing, which was conducted by the W. M. Keck Foundation 
Biotechnology Resource Laboratory (Yale University), confirmed successful cloning. 
The protocol for sample submission included: 
 
DNA sequencing Concentration Amount 
hD-DT / mD-DT plasmid ~ 300 ng/µl 2 µl 
T7 primer 50 ng/µl 2 µl 
H2O  14 µl 
Total  18 µl 
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2.7 Cell Culture Techniques 
2.7.1 Cultivation and Treatment 
All cell culture work was performed in BL-2-approved laminar flow hoods. For 
cultivation, cells were kept in a humidified atmosphere at 37 °C with 5% CO2. All 
media and solution were sterile and endotoxin free. 
Adherent cells were passaged at a confluence of 70 – 80%. Cells were washed 
twice with PBS. RAW 264.7 macrophages were detached from culture flasks using a 
cell scraper, whereas Trypsin/EDTA was used for COS-7 fibroblasts. Cells were re-
plated in fresh medium at a confluence of 10%. 
 
2.7.2 Cell Thawing 
An aliquot of cells was removed from liquid nitrogen (-196 °C) and immediately 
immersed into 37 °C water bath until the medium was completely liquid. Nine ml of 
pre-warmed complete growth medium was added in order to reduce the toxicity of the 
dimethyl sulfoxide (DMSO) contained in the cell solution.  Subsequently, cells were 
centrifuged at 1,000 rpm for 5 min (Beckman Alegra6 centrifuge), resuspended in 
pre-warmed complete growth medium, transferred into cell culture flasks and 
incubated at 37 °C. 
 
2.7.3 Determination of Cell Concentration 
Cells were washed with PBS, detached from cell culture flasks, and suspended in the 
desired medium. An aliquot of 10 µl was placed on the hemacytometer chamber and 
the number of cells determined by counting. The formula for calculating the cell 
concentration in the mixture included: 
 
Table 3: Formula for determination of cell concentration. 
N = n * 104 
(N = number of cells per ml; n = cell number counted in one hemacytometer square) 
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2.7.4 Cryo Stocks of Cells 
A maximal confluence of 90% of cells plated in complete growth medium was 
desired prior to cryo stock preparation. Cells were detached from flasks and 
suspended in cryo medium at a concentration of 1x106 /ml. Cryo medium consisted of 
FBS and 5% DMSO. Aliquots of 1 ml were pipetted into cryo tubes and subsequently 
cooled down. Cryo stocks were stored in liquid nitrogen. 
 
2.7.5 Transient Transfection 
Depending on the cell type, different methods were employed for transfection. 
Successful transfection was determined by GFP detection under a fluorescent 
microscope 48 h later. 
 
2.7.5.1 Transfection of Fibroblasts by Lipofectamine 2000 
The cationic, lipid-based transfection reagent Lipofectamine 2000 was used to 
transfect plasmid DNA into in vitro cell cultures of COS-7 fibroblasts. Lipofectamine 
treatment altered the cellular plasma membrane, allowing nucleic acids to cross into 
the cytoplasm. 
One day before transfection, COS-7 fibroblasts were plated in complete growth 
medium without antibiotics at a concentration of 1x105 /ml. Thus, a cell confluence of 
90-95% was achieved at the time of transfection. Then, 0.8 µg of plasmid DNA 
(either GFP, mMIF or mD-DT plasmid) and 2 µl Lipofectamine 2000 were diluted 
separately in 50 µl of Opti-MEM I Reduced-Serum Medium. After incubating at room 
temperature for 5 min, the diluted plasmid DNA was combined with the diluted 
Lipofectamine 2000. This was succeeded by incubation at room temperature for 20 
min. Subsequently, 100 µl of plasmid DNA / Lipofectamine 2000 complexes were 
added to each well containing COS-7 cells and medium. Cells were cultured at 37 ° 
between 24 h and 48 h after transfection. 
 
2.7.5.2 Transfection of Macrophages by Electroporation 
RAW 264.7 macrophages were transfected with plasmid DNA by Amaxa 
electroporation. Electroporation significantly increases the permeability of the cell 
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plasma membrane by applying an external electrical field, allowing cellular 
introduction of DNA, which would never passively diffuse across the hydrophobic 
bilayer core. 
Preparation of RAW 264.7 macrophages for transfection included the 
following steps: cultivation of cells in complete growth medium, washing of cells 
with PBS, dislodging cells from culture flasks by scraping, counting cells, transferring 
aliquots of 2x106 cells into 15 ml Falcon tubes, centrifuging cells at 1000 rpm at 20 
°C for 10 min. Next, the cell pellet was resuspended in 100 µl room temperature 
nucleofector solution V. Two µg plasmid DNA (either GFP, mMIF or mD-DT 
plasmid) was added and sample transferred into an Amaxa certified cuvette. The 
Nucleofector program D-032 was selected for electroporation. To avoid damage of 
the cells, samples were removed from the cuvette immediately after electroporation 
had finished. After electroporation, transfected macrophages were transferred into 6-
well cell culture plates containing 2 ml pre-warmed complete growth medium per 
well and incubated at 37 °C for 48 h. 
 
2.7.6 Preparation of Cell Lysates 
Preparation of cell lysates for Western blot analysis included the following steps: 
washing of cells with ice cold PBS, lysis of cells by incubation in 200 µl RIPA buffer 
containing protease and phosphatase inhibitors for 30 min at 4 °C, removal of 
genomic DNA and cell debris by centrifugation at 14,000 rpm at 4 °C for 10 min. 
 
2.8 Functional Assays 
2.8.1 Apoptosis Assay 
Roche’s Cell Death Detection ELISAPLUS was used for the detection of D-DT’s effect 
on macrophage apoptosis. This assay is based on a quantitative sandwich-enzyme-
immunoassay-principle, which quantifies histone-complexed DNA fragments (mono- 
and oligonucleosomes) in the cytoplasmic fraction of cell lysates (Figure 9). 
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Figure 9: Principle of the Cell Death Detection ELISAPLUS. The sample (e.g., cell lysate) is placed 
into a streptavidin-coated microplate. A anti-histone-biotin antibody binds to the histone-component of 
the nucleosomes in the sample and simultaneously captures the immunocomplex to the streptavidin-
coated microplate via its biotinylation. Additionally, the anti-DNA-peroxidase antibody reacts with the 
DNA-component of the nucleosomes. Following removal of unbound components by a washing step, 
the amount of nucleosomes is quantitatively determined by the peroxidase retained in the 
immunocomplex. The amount of peroxidase is determined photometrically with ABTS as substrate. 
Abbreviations: HRP, Horseradish peroxidase. Figure modified from Roche. 
 
RAW 264.7 macrophages were transfected with GFP, mMIF or mD-DT 
plasmid. Right after transfection, cells were plated in a 96-well cell culture plate at a 
cell density of 1x105/ well in complete growth medium and incubated at 37 °C for 48 
h. A working solution of 100 mM sodium nitroprusside (SNP) was prepared and 1 µl 
pipetted into each well of the 96-well cell culture plate containing macrophages and 
complete growth medium. Thus, a final SNP concentration of 1 mM was generated. 
Cells were incubated at 37 °C for another 4 h and the ELISA assay was performed. 
Cell medium (containing necrotic cell DNA which had leaked through the cell 
membrane during incubation) was removed and 200 µl lysis buffer added to each 
well. Following an incubation time of 30 min at room temperature, cell lysates were 
centrifuged at 1000 rpm for 10 min. An aliquot of 20 µl from the supernatant 
(cytoplasmic fraction) was transferred into the streptavidin-coated well of a 
microplate. After preparing the immunoreagent according to the manufacturer’s 
recommendations and adding 80 µl to each well, the microplate was covered with an 
adhesive cover foil and incubated under gentle shaking for 2 h at room temperature. 
During this process, the nucleosomes in the supernatant of the cell lysate were bound 
with two monoclonal antibodies, anti-histone (biotin-labeled) and anti-DNA (HRP-
conjugated). Antibody-nucleosome complexes were bound to the microplate by the 
streptavidin. Subsequently, the solution was removed thoroughly by trapping and the 
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microplate washed three times with 250 µl incubation buffer per well in order to 
remove cell components that were not immunoreactive. The samples were incubated 
with 100 µl of HRP substrate (ABTS solution) on a plate shaker until the color 
development was sufficient for a photometric analysis (approximately 10 min). Then, 
100 µl ABTS stop solution was added to each well in the following. The amount of 
colored product (and thus, of immobilized antibody-histone complexes) was 
determined spectrophotometrically at 405 nm. 
 
2.8.2 Vitality Assay 
Cayman’s MTT Proliferation Assay Kit is a colorimetric assay system applicable for 
studying cell viability in an in vitro model. In this assay, cells take up MTT, a yellow 
tetrazole, due to its net positive charge and the plasma membrane potential. 
Intracellular MTT is reduced into an insoluble, purple formazan product by 
NAD(P)H-oxidoreductases in the mitochondria of viable cells. After cell lysis and 
solubilization of these purple crystals into a colored solution, the samples are read on 
a microplate reader. The amount of color produced is directly proportional to the 
number of viable cells. 
Mouse peritoneal macrophages were collected and seeded in a 96-well 
microplate containing complete growth medium at a cell density of 1x105 /well. After 
an incubation at 37 °C for approximately 5-6 hours, macrophages had become 
adherent. Cell medium was then changed to DMEM low glucose, low FBS in order to 
quiescent macrophages for further investigation and incubated overnight. The next 
day, cells were washed three times with PBS. Quiescent cell medium containing 
either recombinant MIF, D-DT, or both MIF and D-DT was added at a final 
concentration of 50 ng/ml. Subsequently, macrophages were incubated at 37 °C for 2 
h. Ten µl of MTT reagent was added, the microplate gently shaken, and the cells 
again incubated for 4 h. After incubation, the formazan produced in the cells appeared 
as dark crystals in the bottom of the wells. The culture medium was carefully 
aspirated from each well to prevent disruption of the cell monolayer. Subsequently, 
100 µl of crystal dissolving solution was added to each well, dissolving the formazan 
crystals and producing a purple solution. The absorbance to each sample was 
measured at 570 nm using a microplate reader. 
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2.9 Protein Chemistry and Immunology Techniques 
2.9.1 Determination of Protein Concentration 
The concentration of protein in solution was measured by a spectroscopic analytical 
procedure according to Bradford (144). The previously red coomassie reagent 
changes and stabilizes into coomassie blue after binding of hydrophobic amino acids 
of protein. Bound coomassie is blue, with an absorption spectrum maximum at 595 
nm, while the unbound forms are green or red. The increase of absorbance at 595 nm 
is proportional to the amount of bound dye, and thus to the amount (concentration) of 
protein present in the sample. 
After diluting the Bradford reagent 1:5 in water, samples were diluted 1:1000 
in Bradford solution. A BSA standard with BSA concentrations from 0 µg/ml to 20 
µg/ml was performed accordingly. After incubation for 5 min at room temperature, 
the absorbance was measured at 595 nm. The concentration of the samples was 
calculated by interpolation from a BSA standard curve (BSA concentration over 
OD595 values). 
 
2.9.2 SDS-PAGE 
Proteins were separated according to their size (and therefore, molecular weight) in an 
externally applied electric field. The NuPAGE system was employed using Bis-Tris 
4-12% polyacrylamide gradient gels. 
Samples were boiled in sodium dodecylsulfate (SDS) sample loading buffer for 
10 min. In this progress, the negatively charged detergent SDS denatures native 
proteins by binding to polypeptides in a constant weight ratio of 1.4 g per 1 g of 
polypeptide. Thus after treatment, polypeptides get a linear structure possessing a 
uniform negative charge density due to SDS. Besides SDS, the reducing agent DTT 
denatures the proteins further by reducing disulfide linkages. After denaturation, 20 µl 
of sample was pipetted into the gel slot and separated at 160 V in NuPAGE/XCell 
SureLock chambers for 10 min followed by 200 V for 50 min. MES running buffer 
was used for small molecular weight proteins in the range of 3-50 kDa. As voltage 
was applied, the polypeptides moved through the gel matrix at different speeds toward 
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the anode determined by their molecular weight. Smaller proteins traveled farther 
down the gel, while larger ones remained closer to the point or origin. One lane was 
reserved for SeaBlue Plus2 marker, a mixture of proteins having defined molecular 
weights and stained so as to form visible, colored bands. 
 
2.9.3 Western Blot 
Proteins separated in SDS-PAGE were transferred to a methanol-activated PVDF 
membrane using the XCell II Blot Module. Proteins maintained the organization they 
had within the gel, but were available for detection. Therefore, SDS-PAGE gel and 
PVDF membrane were stacked in the blot module surrounded by filter papers and 
pads, which were soaked in transfer buffer in order to keep the components moist. 
The inner chamber was also filled with transfer buffer, while ice and ice cold water 
was poured in the outer chamber. The blotting process was run at 40 V for 60 – 90 
min. 
 
2.9.4 Immunodetection 
Following Western blotting, the unspecific binding sites on the PVDF membrane 
were blocked by incubating it in 10 ml blocking buffer for 2 h. The primary antibody 
was diluted at a ratio of 1:1000 in blocking buffer and the membrane was incubated 
with primary antibody solution either for 2 h at room temperature or overnight at 4 
°C. Previous to incubating the blotting membrane with the HRP-coupled secondary 
antibody, it was washed 3 times. The secondary antibody was diluted in blocking 
solution at 1:5000 and incubated with the membrane for 1 h. After washing the 
membrane, proteins were visualized by detecting the chemiluminescence emitted after 
addition of the ECL substrate. If the membrane was re-probed, the membrane was 
incubated in stripping buffer for at least 30 min at room temperature. After thoroughly 
washing the membrane, immunoblotting procedure was repeated.  
 
 42 – Materials and Methods   
2.9.4.1 Quantification of Band Density 
To quantify the bands obtained via Western blot analysis, ImageJ software analysis 
(http://rsb.info.nih.gov/ij/) was applied. The area under the curve (AUC) of the 
specific signal was corrected for the AUC of the loading control. The value for the 
‘GFP’ condition was set as 1, and other conditions were recalculated correspondingly 
to allow ratio comparisons. 
 
2.9.5 Enzymatic Activity 
p-Hydroxyphenylpyruvate (HPP) served as a substrate for the tautomerase activity of 
human MIF, human D-DT and murine D-DT. Therefore, 64 µM dilutions of each 
protein in PBS were prepared. 
 
2.9.5.1 Tautomerase Activity on HPP without Inhibitor 
The tautomerase reaction was set up as followed and activity of the protein was 
measured by the difference in absorbance at 305 nm in a spectrophotometer over the 
course of 3 min: 
 
Tautomerase reaction Amount 
Sodium borate buffer 452 µl 
H2O 77 µl 
Protein 1 µl 
HPP 17 µl 
 
2.9.5.2 Tautomerase Activity on HPP with 4-IPP or ISO-1 
4-IPP and ISO-1 were diluted in DMSO to a final concentration of 100 mM. For their 
administration in the tautomerase assay, the stock solution was diluted further 
according to the following tables: 
 
Protein, concentration 4-IPP, concentration Protein: inhibitor ratio 
64 µM 64 µM 1:1 
64 µM 320 µM 1:5 
64 µM 640 µM 1:10 
64 µM 6.4 mM 1:100 
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Protein, concentration ISO-1, concentration Protein: inhibitor ratio 
64 µM 6.4 mM 1:100 
64 µM 64 mM 1:1000 
64 µM 640 mM 1:10,000 
 
Protein and inhibitor were combined and incubated at room temperature for 10 
min. Subsequently, the tautomerase reaction was set up and remaining activity of the 
protein was measured photometrically: 
 
Tautomerase reaction Amount 
Sodium borate buffer 452 µl 
H2O 77 µl 
Protein/inhibitor solution 1 µl 
HPP 17 µl 
 
2.10 In vivo Mouse Experiments 
All experiments were performed in compliance with the guidelines of the Yale 
University Institutional Animal Care and Use Committee. 
 
2.10.1 LPS Shock 
LPS shock experiments were performed with 6 - 8 week old female BALB/c mice. 
First, 200 µl of anti-mD-DT serum or normal rabbit serum (NRS) were injected 
intraperitoneally 2 h prior to LPS injection. Then, 20 mg/kg LPS (0111:B4) was 
applied for survival experiments. Subsequently, mice were observed for the following 
2 weeks. 
 
2.10.2 Isolation of Peritoneal Macrophages 
Peritoneal macrophages were isolated from 8 – 12 week old female BALB/c mice. 
Three ml of thioglycollate medium was injected intraperitoneally causing peritonitis 
in the following days. Four to five days past injection, mice were euthanized by 
isoflurane inhalation, sanitized with 70% ethanol and abdominal fur removed. Five ml 
of sterile ice cold PBS was injected into the peritoneal cavity and subsequently 
aspirated, now containing inflammatory cells. The PBS injection and aspiration was 
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repeated 2 - 3 times until aspirated solution appeared clear indicating a decreased 
number of cells. Then, the PBS/cell solution was centrifuged at 1200 rpm for 5 min, 
PBS removed, the cell pellet re-suspended in complete growth medium, and 
macrophages cultured at 37 °C for further use. 
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3 RESULTS 
3.1 D-DT in Apoptosis 
Apoptosis is crucial for host survival and has been suggested to limit inflammatory 
responses (69). Prevention of cell death by MIF is well documented and a number of 
studies have been published to date on MIF’s molecular mechanisms in various 
models of apoptosis. MIF has been shown to protect cells from apoptosis by 
preventing cytoplasmic p53 accumulation (62, 69) and by stimulating anti-apoptotic 
proteins (70). Thus, it was one goal of this thesis to investigate D-DT’s effects on 
apoptosis. Therefore, human D-DT and murine D-DT cDNAs were first cloned into 
mammalian expression vectors. Subsequently, fibroblasts and macrophages were 
transfected with these generated plasmids. Protein overexpression was confirmed by 
Western blotting and the effect of D-DT was measured after apoptosis induction in an 
in vitro model. 
 
3.1.1 Cloning of D-DT into Mammalian Expression Vectors 
The first step was to generate human and murine D-DT plasmid constructs for 
specific D-DT protein overexpression in mammalian cells. Hence, hD-DT and mD-
DT cDNAs were directly inserted into the plasmid vector pcDNA3.1/V5-His-
TOPO® using the method of TA Cloning. For PCR, primers were designed with a 3’ 
stop codon, so that hD-DT and mD-DT were expressed as native proteins. For TA 
Cloning, Taq polymerase was used which has a nontemplate-dependent terminal 
transferase activity that adds a single deoxyadenosine (A) to the 3’ end of PCR 
products. The linearized vector possesses single, overhanging 3’ deoxythymidine (T) 
residues and, therefore, allows PCR inserts to ligate efficiently with the vector. 
Moreover, topoisomerase is covalently bound to the vector, helping to efficiently 
clone PCR products. 
Transformants were analyzed for the correct orientation of the PCR product by 
DNA sequencing, and then transfected into mammalian cells for expression. 
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3.1.2 D-DT is Overexpressed in Cos-7 Fibroblasts 
3.1.2.1 GFP Transfection Rate of 70% 
Mammalian Cos-7 fibroblasts were transfected with MIF, D-DT or GFP plasmid. 
GFP served as a reporter gene indicating success of transfection, because the resulting 
protein exhibits bright green fluorescence when exposed to blue light at a wavelength 
of 395 nm under a fluorescent microscope. The fibroblast transfection rate was 
estimated to be approximately 70% (Figure 10). 
  
 
Figure 10: GFP detection in Cos-7 fibroblasts. Cos-7 fibroblasts were transfected with GFP plasmid 
using Lipofectamine 2000. Prior to transfection, GFP plasmid (final concentration: 0.016 g/l) and 
Lipofectamine 2000 (final concentration: 0.04 g/l) were diluted in Opti-MEM 1 Reduced Serum 
medium and incubated at room temperature for 5 min. Dilutions were combined in a 1:1 ratio and 
further incubated for 20 min. Then, 100 µl of DNA/Lipofectamine 2000 complexes were added to 90% 
confluent Cos-7 cells, which were cultured on a 24-well plate in complete growth medium without 
antibiotics. Subsequently, cells were incubated at 37 °C and imaged 48 h later. Green fluorescence 
indicates GFP-expressing fibroblasts due to successful plasmid transfection. The transfection rate was 
estimated to be approximately 70%. Left panel: bright-field. Middle panel: fluorescence for GFP. Right 
panel: overlay. A representative experiment is shown. 
 
3.1.2.2 3.8-fold Overexpression of D-DT in Fibroblasts 
Next, I confirmed D-DT protein overexpression in Cos-7 fibroblasts. Cells were 
transfected with MIF or D-DT plasmids as described for GFP transfection in Figure 
10. Twenty-four h and 48 h after transfection, cells were lysed and proteins detected 
by Western blotting. 
D-DT plasmid transfection of Cos-7 fibroblasts resulted in 3.7-fold 
overexpression of D-DT protein levels 24 h later (Figure 11). Forty-eight h post 
transfection, cytosolic D-DT protein content was detected to be 3.8-fold higher than 
control. These results are consistent with MIF protein levels as a 5.1-fold and a 4.1-
fold increase of MIF content was observed in MIF plasmid transfected cells 24 h and 
48 h after transfection. 
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Figure 11: Overexpression of D-DT and MIF in Cos-7 fibroblasts. Cos-7 fibroblasts were 
transfected with MIF, D-DT plasmid or a control plasmid (GFP). Cells were lysed and total cell protein 
extracts were subjected to Western blot analysis detecting MIF and D-DT 24 h and 48 h after 
transfection. Below each Western blot, the respective band densitometry analysis performed with 
ImageJ software is shown. The amount of specific signal for MIF and D-DT was corrected for sample 
loading. The value for the ‘GFP’ condition 24 h and 48 h after transfection was set as 1. 
 
3.1.3 D-DT is Overexpressed in RAW 264.7 Macrophages 
3.1.3.1 GFP Transfection Rate of 35% 
Nucleofection, which is based on the physical method of electroporation, was used to 
transfer MIF, D-DT or GFP plasmid into RAW 264.7 macrophages. Fluorescence 
microscopy of transfected cells allowed the monitoring of DNA transfer efficiency. A 
transfection rate of 35% was estimated by cell counting (Figure 12). 
 
 
Figure 12: GFP detection in RAW 264.7 macrophages. Cells were nucleofected with GFP plasmid 
and 48 h later analyzed by fluorescence microscopy. Transfection efficiency was estimated to be 35%. 
Before transfection, RAW 264.7 macrophages were cultured in complete growth medium. Following 
dislodgement from the flask, cell pellets of aliquots of 2x106 cells were generated by centrifugation. 
Cell pellets were resuspended in 100 µl Nucleofector Solution V, combined with 2 µg GFP plasmid 
and transferred to an Amaxa certified cuvette. Nucleofector program D-032 was selected for 
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transfection. Immediately following nucleofection, macrophages were transferred into 6-well plates 
containing pre-warmed culture medium at a final concentration of 1x106 cells/ml. Subsequently, cells 
were incubated at 37 °C. Left panel: bright-field. Middle panel: fluorescence for GFP. Right panel: 
overlay. A representative experiment is shown. 
 
3.1.3.2 1.4-fold Overexpression of D-DT in Macrophages 
Transient transfection of RAW 264.7 macrophages was generated by electroporation 
and overexpression analyzed by Western blotting 48 h post transfection. No increase 
of MIF protein levels was observed in MIF-transfected cells (Figure 13A). However, 
D-DT protein was measured to be 1.4-fold overexpressed in D-DT-transfected cells 
compared to control cells (Figure 13B). Of note, endogenous MIF and D-DT are 
visualized in GFP-transfected cells. 
 
 
Figure 13: Analysis of MIF and D-DT content in RAW 264.7 macrophages. Cells were transfected 
with MIF, D-DT plasmid or control plasmid (GFP) and analyzed for MIF (A) and D-DT (B) 
overexpression by Western blotting 48 h after transfection. The bands visualized via Western blot were 
subjected to band densitometry analysis with ImageJ software. The amount of specific signal for MIF 
and D-DT was corrected for sample loading. The value for the ‘GFP’ condition was set as 1. 
 
3.1.4 D-DT Does Not Protect from Apoptosis 
After successfully generating a D-DT plasmid and confirming plasmid transfection 
and protein overexpression, my next objective was to determine, whether D-DT 
influences apoptosis. Following plasmid transfection, protein levels increased in 
macrophages accordingly and successive apoptosis studies were performed. 
Methodically, transfected RAW 264.7 macrophages were stimulated with the NO 
donor SNP and the rate of apoptosis measured by the detection of nucleosomes. As 
shown in Figure 14, overexpression of D-DT in macrophages did not reduce the level 
of apoptosis. Conversely, overexpression of MIF in likewise stimulated macrophages 
  
 Results - 49 
led to a decrease of apoptosis rate similar to that of GFP-transfected non-stimulated 
cells. This is in agreement with prior reports, which demonstrated that MIF protects 
macrophages from NO-induced apoptosis by preventing p53 accumulation (62, 69) 
and through PI3K/Akt signaling pathway (70, 72). However, these results suggest that 
D-DT does not protect transfected macrophages from SNP-induced apoptosis. 
Therefore, these reports provide first evidence of opposing actions of D-DT and MIF, 
and might distinguish D-DT’s effects from those of MIF. 
 
 
 
Figure 14: D-DT has no anti-apoptotic function. RAW 264.7 macrophages were transfected with D-
DT plasmid or control plasmids (GFP or MIF). 48 h post transfection, apoptosis was induced by 1 mM 
SNP and cells incubated for 4 h. Apoptotic levels were measured by detecting the formation of 
nucleosomes. Results are expressed as mean±S.E. of three independent experiments. No statistical 
significance could be determined, p>0.05. 
 
3.2 D-DT Enhances Cell Viability 
Apart from its anti-apoptotic functions, MIF has also been implicated in maintenance 
of cell viability and survival and, thus, in the prolongation of inflammatory reactions 
in response to invading pathogens. In vivo LPS administration leads to greater 
production of pro-inflammatory cytokines (TNFα, IL-1β, and PGE2) in wildtype mice 
compared to MIF-deficient mice (69). Of note, MIF was also shown to mostly act pro-
proliferative (e.g., by promoting integrin-dependent cell cycle progression) (145). 
Additionally, human tumors (e.g., colorectal or prostatic adenocarcinoma cells) had 
increased MIF levels, suggesting MIF’s pro-tumorigenic activity (31, 32). As with 
MIF, it seemed important to gain a broader understanding of the role D-DT plays in 
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cell viability and, thus, to determine whether D-DT affects cell death or leads to cell 
survival. Herein, D-DT’s effect on macrophage viability was addressed. 
In an in vitro assay, stimulation of peritoneal macrophages with recombinant 
D-DT resulted in a higher level of cell viability compared to control (Figure 15). This 
increase was more pronounced than MIF-induced progression of macrophage 
viability, indicating quantitative differences between the effects of MIF and D-DT. 
Interestingly, adding MIF and D-DT simultaneously to macrophages led to an even 
higher increase of cell viability. These data point to a potential viability-supporting 
function of D-DT that is even more distinct than that of MIF, and also suggest 
additive effects of MIF and D-DT. 
 
 
Figure 15: D-DT enhances macrophage viability. Peritoneal macrophages were collected from 8-12 
weeks old BALB/c mice 4-5 days after thioglycollate-induced peritonitis. 24 h past isolation, 
macrophages (1x106/ml) were stimulated with the indicated recombinant proteins for 2 h (final 
concentration: 50 ng/ml) and cell viability assessed by photometrical measurement of tetrazolium salt 
reduction. Results are expressed as mean±S.E. of three independent experiments. Statistical 
significance was determined for D-DT and MIF + D-DT treated cells against untreated cells by 
Student’s t-test, *p<0.05. 
 
3.3 Tautomerization of p-Hydroxyphenylpyruvate 
MIF catalyzes the tautomerization of the non-physiological substrate HPP (137). Its 
overall three-dimensional structure, especially the protein’s amino terminal region 
around Pro1, is crucial for this enzymatic activity (122). This catalytic base is 
conserved in D-DT, resulting in similar tautomerase activity. Because D-DT has been 
identified as a structural homologue of MIF, and thus as a member of the 
MIF/tautomerase superfamily (135), it was of special interest to investigate D-DT’s 
catalytic activity on HPP continuatively in close comparison to MIF. Moreover, the 
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active site of MIF around Pro1 has been associated with its pro-inflammatory actions 
(123-125). Therefore, prototypic small molecule inhibitors have been designed that 
bind to the protein’s amino terminal region and, thus, block MIF’s effects. Co-effects 
or interference of these inhibitors with D-DT, specifically with D-DT’s tautomerase 
activity or D-DT’s potential downstream actions, have not been reported to date. 
Taken together, these previous findings suggested that it would be beneficial to 
further investigate MIF’s and D-DT’s tautomerase activity in a comparative manner. 
This thesis focused specifically on quantitatively comparing D-DT’s and MIF’s 
enzymatic activity on the one hand, and the effects on D-DT of two of MIF’s small 
molecular inhibitors, 4-IPP and ISO-1, on the other. Assessing the rate of enzymatic 
tautomerization of the substrate HPP in the presence of different inhibitor 
concentrations served this purpose. Substrate turnover was measured photometrically 
over the course of 3 min. 
 
3.3.1 Human and Murine D-DT Tautomerase HPP 
A direct comparison of human MIF’s, human D-DT’s and murine D-DT’s 
tautomerase activity was performed using the HPP tautomerase assay (Figure 16A). 
Comparing their ability to catalyze the tautomerization of HPP revealed that human 
MIF has the highest enzymatic activity (hMIF = 4.3±1.1 Δ305nm/min/µM). Human 
D-DT possessed only 11% of human MIF's enzymatic ability, whereas murine D-DT 
achieved 76% of the tautomerase activity of human MIF (hD-DT = 0.5±0.1 
Δ305nm/min/µM, and mD-DT = 3.3±1.5 Δ305nm/min/µM). These results confirmed 
the tautomerase activity of all three proteins and substantiated the HPP tautomerase 
assay as an adjuvant tool for further inhibitory studies of this enzymatic activity. 
 
3.3.2 D-DT is Partially Sensitive to MIF Tautomerase Inhibitors 
My next objective was to use the same HPP tautomerase assay to investigate whether 
human D-DT and murine D-DT are sensitive to human MIF-catalytic site inhibitors. I 
studied the inhibitory effects of 4-IPP and ISO-1, two of the many small molecular 
antagonists of MIF’s enzymatic active site reported, on the biological activities of 
human MIF, human D-DT and murine D-DT. 4-IPP served as a suicide substrate for 
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MIF, resulting in the covalent modification of the catalytically active N-terminal 
proline (127). The competitive inhibitor ISO-1 was one of the first discovered MIF 
antagonists and is the best characterized. It reversibly binds to MIF and also interferes 
with MIF’s biological functions in vitro and in vivo (81, 123). 
Combining human MIF and 4-IPP at a 1:1 ratio led to a pronounced decrease 
of human MIF’s enzymatic activity (95%) (Figure 16B). At higher inhibitor 
concentrations (1:1 and 1:5 ratios), 4-IPP abolished human MIF’s enzymatic activity. 
Likewise, 4-IPP significantly inhibited the tautomerase activity of both human D-DT 
and murine D-DT, but with a greater inhibitory effect on murine D-DT. A 1:1 murine 
D-DT/4-IPP ratio was sufficient to reduce the enzymatic activity significantly, 
whereas a 10-fold 4-IPP excess was needed for the same reduction of human D-DT. 
Next, the competitive inhibitor ISO-1 inhibited human MIF significantly when added 
in 100-, 1000- or 10,000-fold molar excess (Figure 16C). In contrast, human D-DT’s 
and murine D-DT's activity was not affected. In summary, these findings suggested 
that both human D-DT and murine D-DT are susceptible to the inhibitory effects of 4-
IPP, however, at a reduced rate. ISO-1 obtains a selective interaction with the human 
MIF tautomerase site. 
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Figure 16: Tautomerization activity of human MIF, human D-DT, and murine D-DT measured 
with the substrate HPP. A) The enzymatic activity of the protein (78 nM) was measured by the 
difference in absorption at 305 nm over the course of 3 min. Data are mean±SD of six independent 
experiments. B) The small molecule inhibitor 4-IPP was pre-incubated for 10 min at room temperature 
with human MIF, human D-DT or murine D-DT at increasing concentrations. Data are mean±SD of 
triplicate independent measurements. C) The small molecule inhibitor ISO-1 was pre-incubated for 10 
min at room temperature with human MIF, human D-DT or murine D-DT at 100-, 1000- or 10,000-fold 
molar excess, respectively. Data are mean±SD of triplicate independent measurements. The p values 
were calculated by Student’s t-test (protein vs. protein + inhibitor), ***p<0.001, **p<0.01. 
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3.4 Neutralization of D-DT Protects Mice from LPS-Shock 
The LPS-shock model has frequently been used to investigate MIF’s effects in acute, 
severe inflammatory responses as measured by mice survival and mortality. 
Following LPS challenge, MIF is rapidly released from immune cells and increased 
MIF-levels are observed in the blood circulation (11, 13, 30). Similarly, it has been 
reported that bone marrow-derived macrophages secrete D-DT in response to LPS 
(116). The pattern of release of D-DT is similar to that reported of MIF, exhibiting a 
bell-shaped curve peaking at 16 h after pro-inflammatory stimulus. Therefore, in this 
thesis, it was of interest to validate whether neutralization of D-DT, like neutralization 
of MIF, protects mice from LPS shock. The herein administered specific polyclonal 
antibody had previously been reported not to show any cross-reactivity to MIF (116). 
Figure 17 illustrates that, indeed, administration of anti-D-DT antibody significantly 
increased survival rate from 20% to 79% following challenge of an LD80 dose of LPS. 
This degree of protection is comparable to what was achieved previously with anti-
MIF (11).  
 
 
Figure 17: Neutralization of D-DT protects mice in a model of lethal endotoxemia. Female 
BALB/c mice (6-8 weeks) were intraperitoneally injected with 200 µl of anti-mD-DT serum or control 
serum. Two h later, LPS was injected (20 mg/kg). Mice were observed for 2 weeks. Data points are 
from three independent experiments, each of which included 5-10 mice per treatment group. Survival 
was 75% (15 of 20) in mice treated with anti-D-DT antibody, and 19% (4 of 21) in mice treated with 
control antibody. P<0.0001, Kaplan-Meier. 
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4 DISCUSSION 
In 1993, a new enzyme that specifically tautomerizes the D-isomer of dopachrome 
was found in human tissue (132). It was named D-DT due to this first discovery. Two 
years later, cloning and sequencing of a cDNA encoding D-DT disclosed sequence 
homology with MIF (146). Sugimoto et al. determined the X-ray crystal structure of 
D-DT with a result of strong structural homology between MIF and D-DT (135). As a 
consequence, it was presumed that D-DT might play a similar physiological role to 
the immunoregulator MIF. A few observations support the hypothesis that MIF and 
D-DT share some biological abilities. First, the mRNA and protein levels of D-DT are 
unchanged in mif knockout cells compared to wildtype control cells (116). Second, 
both proteins are released constitutively at a low level and are efficiently secreted 
after stimulation with LPS from macrophages. Moreover, the depletion of either MIF 
or D-DT by siRNA results in similar effects, precisely in the transcriptional regulation 
of IL-8, both involving the receptor CD74 (140).  
More recently, studies of B cell apoptosis and monocyte arrest showed that 
neutralization or genetic deletion of MIF does not completely abrogate downstream 
activation responses (20, 147). The deletion of the MIF receptor CD74 produces a 
more pronounced phenotype than MIF deficiency. This observation may be explained 
by a second MIF-like ligand, which possibly may be D-DT (87). As there is very little 
knowledge about the physiological role of D-DT to date, further studies would be 
useful to elucidate D-DT’s precise role. 
 
4.1 D-DT was Overexpressed for Apoptosis Studies 
4.1.1 TA Cloning Generates D-DT Plasmid 
Prior to functional studies of D-DT (e.g., its effect on apoptosis) the D-DT cDNA was 
cloned into a mammalian expression vector. Mammalian cells were subsequently 
transfected with the newly generated plasmids and protein overexpression confirmed. 
In this thesis, TA Cloning was used to generate D-DT plasmid constructs. It is an easy 
and quick subcloning technique that clones PCR amplified inserts directly into 
linearized vectors without the use of restriction enzymes (148). The complementary 
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base pairs thymine (T; at both ends of the linearized vector) and adenine (A; at both 
ends of the PCR product) hybridize and become ligated together. Because no 
restriction sites are needed, shorter primers can be utilized, which facilitates the 
procedure. On the downside, no directional cloning is guaranteed and the gene is 
inserted in reverse direction in 50% of all successfully cloned vectors. Consequently, 
DNA sequencing is needed to confirm correct orientation of the gene. 
 
4.1.2 Lipofectamine 2000 Transfects Fibroblasts 
In this thesis, the reagent Lipofectamine 2000 was applied for Cos-7 fibroblast 
transfection. It is a cationic liposome formulation that functions by forming a complex 
with net negatively charged nucleic acid, allowing it to overcome the electrostatic 
repulsion of the cell membrane and, thus, to be taken up by the cell (149). With the 
help of Lipofectamine 2000, plasmid DNA reaches the nucleus of the cell, becomes 
accessible to the transcriptional machinery and, thus, D-DT is expressed. Also, in 
actively dividing cells, such as Cos-7 fibroblasts, transfected DNA simply becomes 
trapped in the nucleus following the reassembly of the nuclear envelope at the end of 
mitosis. However, Lipofectamine 2000 has been shown to promote penetration of 
DNA through intact nuclear envelopes. It provides a rather chemical than physical 
method of cell transfection and, thus, is considered to be gentler, which results in high 
transfection efficiencies and high levels of transgene expression without excessive 
cytotoxicity. In Cos-7 fibroblasts, a transfection rate of approximately 70% was 
achieved, which was indicated by GFP fluorescence. However, a few scientists 
recently supposed that GFP fluorescence overestimates transfection efficiency. 
Subsequent Western blotting confirmed protein overexpression by visualizing 3.7-
fold and 3.8-fold increased D-DT and 5.1-fold and 4.1-fold increased MIF levels, 24 h 
and 48 h after fibroblast transfection. These results emphasize Lipofectamine 2000’s 
utility in fibroblast transfection, as a high transfection rate of viable cells results in 
high protein overexpression. 
 
4.1.3 Macrophage Transfection Results from Nucleofection 
In contrast to Cos-7 fibroblasts, RAW 264.7 macrophages were transiently transfected 
with plasmids using the Nucleofector technology, which transfers plasmid DNA 
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directly into the cell nucleus. It uses a combination of an electric pulse and the 
appropriate, cell-type specific media, which together decrease the toxicity of the 
otherwise harsh method of electroporation leading to excessive cell death (150). 
Nucleofection promotes efficient transfection of difficult-to-transfect cells, such as 
immune cells, when gentler methods give poor results. Nevertheless, cell death is 
more frequent during nucleofection than during lipid-based methods. In this thesis, 
macrophages were transfected by nucleofection and a transfection rate of 35% was 
estimated by cell counting. Subsequent protein detection by Western blotting could 
not confirm increased MIF levels. Nevertheless, it demonstrated a slight 
overexpression of D-DT (1.4-fold increased D-DT levels), which was lower compared 
to fibroblast transfection by Lipofectamine 2000, as cell mortality rate was higher and 
transfection efficiency significantly lower in nucleofection-transfected cells. 
 
4.2 MIF Acts Anti-Apoptotically 
Previous studies have linked MIF’s pro-inflammatory actions to its ability to protect 
immune cells from apoptosis and, thus, to prolong the inflammatory response. So far, 
several mechanisms of MIF action have been described: MIF prevents p53 
accumulation in the cytoplasm (62, 69) and cytochrome c release from mitochondria 
(71). It also promotes the anti-apoptotic factors Bcl-2 (70) and NF-κB (72). In order 
to study D-DT’s functional properties in comparison to MIF, it was indispensable to 
establish a reliable experimental setup that was consistent with previously reported 
signaling ways of MIF. Such a system would allow confirmation or refutation of D-
DT’s functional similarities to MIF, which are suggested by structural homology and 
previous reports of action of both proteins. 
To this end, macrophages were first transfected with either MIF or D-DT 
plasmids using nucleofection. As discussed before, cell transfection led to cell death 
and stress of the surviving macrophages, that ingested the plasmid. Hence, a 
transfection rate of 35% and a 1.4-fold overexpression of D-DT were achieved. This 
is consistent with previously reported results of experiments using identical materials 
and experimental conditions. Following transfection, apoptosis was induced by the 
NO donor sodium nitroprusside. Since Hudson et al. and Mitchell et al. reported that 
MIF protects macrophages from NO-induced apoptosis by preventing p53 
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accumulation (62, 69) it was assumed that MIF decreases apoptotic levels in this 
analogous experimental setup. Subsequently, the level of macrophage apoptosis was 
measured by detecting the formation of nucleosomes in the cytoplasm. As expected, 
incubation of control-transfected macrophages with SNP led to increased apoptotic 
levels compared to non-SNP treated cells. Second, MIF-transfected macrophages 
showed almost baseline apoptotic levels. However, previous Western blotting did not 
show MIF to be overexpressed following plasmid transfection. The fact that apoptotic 
levels are higher in SNP-treated control-transfected cells than in MIF-transfected 
macrophages indicates that the physiological MIF content alone is not sufficient to 
reduce apoptosis to baseline. Various reasons might account for the unsuccessful 
detection of overexpressed MIF levels. One of them might be that the blotting 
membrane was not able to detect overexpressed MIF levels due to limits of its 
sensitivity or to its saturation. Of note, physical cell stress by nucleofection did not 
diminish MIF’s effect on apoptosis, as indicated by lower rate of apoptosis. These 
results are consistent with previous reports about MIF’s functions. 
 
4.2.1 D-DT does not Diminish Apoptosis 
In contrast to MIF, D-DT did not decrease the level of NO-induced apoptosis in 
macrophages, even despite 1.4-fold protein overexpression. Apoptotic levels of D-DT 
transfected macrophages were comparable to those of control-transfected cells, which 
had been treated with SNP. It might be speculated that higher concentrations of D-DT 
are needed to protect from apoptosis, that D-DT does not impact NO-mediated 
apoptosis induction (or even apoptosis) at all, or that the nucleofection treatment of 
macrophages might have altered cell function in a way that made them less 
susceptible to subsequent D-DT effects. Whatever the reason, apoptotic levels of D-
DT transfected macrophages remained high. 
This is the first report on D-DT’s effect on apoptosis. To validate these results, 
it would be useful to investigate D-DT’s role in various experimental setups. The 
effects of D-DT can be investigated in knockdown experiments with e.g., siRNA, or 
by using different cell lines, different ways of apoptosis induction, or by the 
administration of small molecule inhibitors. Also, its effects on different pro- and 
anti-apoptotic proteins, such as e.g., p53, Bcl-2 or NF-κB, can be determined, which 
would possibly elucidate D-DT’s molecular mechanisms of action. Furthermore, 
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detecting the influence of recombinant D-DT (instead of overexpressed D-DT) on the 
level of apoptosis may provide a beneficial tool to investigate D-DT’s abilities. 
Nevertheless, my data provide first insights into the biological functions of D-DT. 
 
4.3 D-DT Enhances Macrophage Viability 
Previous studies have demonstrated that MIF prolongs inflammatory responses by 
enhancing viability and survival of immune cells (69). MIF causes macrophages to 
release higher levels of pro-inflammatory cytokines, such as TNFα, IL-1β, and PGE2. 
MIF is also involved in cell cycle progression through sustained ERK activation and 
cyclin D1 expression (145). However, MIF also interacts with JAB1 (75). 
Quantitative analysis of MIF level showed that it is overexpressed in human tumors, 
indicating tumor-supportive and, thus, pro-proliferative functions of MIF (31, 32). So 
far, little is known about D-DT’s role in cell viability, the prolongation of 
inflammatory responses, or cell cycle regulation. So far, only a few publications have 
linked D-DT to proliferation. Coleman et al. suggested a biological role for MIF and 
D-DT in NSCLC by reporting that both proteins were required for expression of 
proangiogenic factors, such as CXCL8 and VEGF (140). Moreover, D-DT has been 
reported to affect colorectal cancer disease progression through COX-2 expression 
(141). Aside from those, no specific studies of D-DT’s effect on cell viability, or 
sustained inflammation have been reported to date. 
To fill this void, peritoneal macrophage viability was assessed in vitro in 
response to MIF, D-DT, or simultaneous stimulation by recombinant proteins. It was 
observed that MIF-treatment resulted in increased cell viability, which is in accord 
with previous reports on MIF’s functions. Interestingly, stimulation of macrophages 
with recombinant D-DT led to a more pronounced viability compared to that of MIF. 
This observation indicates that D-DT, like MIF, may enhance cell viability and 
survival. It further proposes that D-DT’s effects may be more distinct compared to 
those of MIF. Therefore, it might be suspected that D-DT favors prolonged 
inflammatory responses similar to MIF. However, as these are one of the first reports 
on D-DT’s functions, further studies are needed to validate this statement. It would be 
interesting to study whether D-DT also leads to the release of pro-inflammatory 
cytokines, resulting in enhanced inflammatory responses. In this case, D-DT’s effects 
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on macrophages as well as on other immune cells should be investigated, as this 
would give more precise insight into D-DT’s regulatory role in inflammation. 
Moreover, it remains uncertain which signal transduction pathways might explain this 
result, as there is very little knowledge about D-DT’s intracellular effects at all. For 
example, D-DT might enhance macrophage viability due to its downstream effect on 
ERK or p53. Another possibility is that D-DT influences completely different cellular 
factors or mechanisms that have not yet been discovered. A study of D-DT’s 
intracellular mechanisms shows that D-DT-induced CXCL8 expression requires JNK, 
c-JUN and AP-1 as well as the CD74 receptor (140). The discovery that CD74 is 
important for D-DT’s downstream effects raises the question whether D-DT, like 
MIF, is a CD74 ligand. Recent observations strengthen the hypothesis that CD74 
might have a second ligand, because deletion of the receptor abrogates downstream 
MIF effects more significantly than neutralization or genetic deletion of MIF alone 
(147, 151). In 2011, it was demonstrated that D-DT binds CD74 with high affinity, as 
well as the intracellular transcription regulator JAB1 (87). However, it remains for 
further investigation whether binding of D-DT to CD74 is involved in signaling 
leading to enhanced cell viability. 
Moreover, my data show that incubation of macrophages with MIF and D-DT 
simultaneously increased cell viability even more compared to treatment with only 
one protein. These findings may suggest additive effects of MIF and D-DT and, thus, 
might lead to the conclusion that both proteins support each other in enhancing cell 
viability. However, subsequent experiments are needed as well to confirm this 
possibility. 
Although all of these conclusions support the possibility of D-DT having a 
viability-supporting function, the experimental methods need to be considered. The 
MTT proliferation assay measures cell viability by colorimetric detection of tetrazole 
salt metabolism in mitochondria. As a result, altered mitochondrial function, 
potentially caused by D-DT, might mimic cell viability and might lead to 
overestimated viability levels. Further studies of D-DT in different experimental 
settings are necessary in order to further evaluate its functions. 
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4.4 MIF and D-DT are Structural Homologues 
4.4.1 Quantitative Differences in Tautomerase Activity 
MIF and D-DT have been shown to share a similar three-dimensional structure and 
were, thus, classified as members of the MIF/tautomerase superfamily (115). Due to 
their structural homology, both proteins were identified as enzymes catalyzing the 
tautomerization of D-dopachrome and HPP (136, 137). However, no detailed 
quantitative studies and comparisons of MIF’s and D-DT’s enzymatic activities have 
been performed to date. In this thesis, I report that human D-DT’s enzymatic activity 
on HPP is approximately 10 times lower than that measured for MIF, whereas the 
tautomerase activity of the murine D-DT is approximately 25% less than that of MIF. 
These findings suggest that differences, most likely the slight structural differences, 
exist between these three proteins and cause enzymatic distinction. 
It previously was shown that the N-terminal proline which resides within a 
hydrophobic, substrate-binding pocket (122, 152, 153) functions as a catalytic base in 
the tautomerization of D-dopachrome and HPP (121). The proline residue is well 
conserved between MIF and D-DT, although a detailed comparison revealed 
significant differences in the environment around the active site, the intersubunit 
contacts, and the charge distribution on the molecular surface (135). In human MIF 
the active site pockets are positively charged, although non-charged regions also have 
been reported. In contrast, human D-DT shows a widely distributed negatively 
charged surface. Only the regions around the active sites are positively charged. In 
human MIF five distinct amino acids are implicated in HPP substrate contact: Pro1, 
Lys32, Ile64, Tyr95 and Asn97 (122). Human D-DT shares three of these five amino 
acids (Pro1, Lys32 and Ile64) with human MIF. However, two residues are absent. 
Tyr95 is replaced by Ile95, and Asn97 by Ile97. Moreover, MIF and D-DT show 
differences in the theoretical isoelectric points of their protein sequences. Human MIF 
possesses an isoelectric point of pH 7.7, whereas human D-DT and murine D-DT 
carry no net electric charge in a slightly acidic environment (human D-DT: pH 6.7 
versus murine D-DT: pH 6.1). At pH 6.2 during the HPP tautomerase assay, MIF's 
and D-DT's amino acid residues show a specific charge, which results in either 
facilitating or aggravating substrate turnover. Taken together, these slight structural 
differences might suggest possible explanations for the diverse interaction of the 
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substrate HPP with the catalytic sites of the proteins and, thus, the different enzymatic 
activities of human MIF, human D-DT and murine D-DT. 
 
4.4.2 Tautomerase Inhibitors Affect D-DT to Lesser Extent 
In addition, the prior reported slight structural differences between MIF and D-DT 
might as well account for the diverse inhibition of their tautomerase activity by 4-IPP 
and ISO-1. These two proteins have been characterized as catalytic inhibitors of MIF, 
which operate by blocking its amino-terminal tautomerase region (123, 127). As 
previously described in this thesis, the covalent MIF inhibitor 4-IPP reduces D-DT’s 
tautomerase activity significantly (albeit at higher inhibitor concentrations compared 
to MIF), whereas the competitive MIF inhibitor ISO-1 is selective for MIF. These 
results indicate that low 4-IPP concentrations result in augmented inhibition of MIF, 
while excessive use of 4-IPP inhibits both proteins. The different inhibitory properties 
of ISO-1 on MIF and D-DT might provide the possibility of specific inhibition of 
MIF’s enzymatic activity while leaving D-DT unaffected. This could provide a useful 
tool for isolating and investigating D-DT’s effects in future research challenges.  This 
also suggests the possibility of developing therapeutically beneficial pharmacological 
inhibitors in situations where specific inhibition of one protein, but not the other, is 
intended.  
 
4.4.3 Enzymatic Inhibitors Might Impact Biological Function 
The tautomerization site centered around Pro1 in MIF has been linked to some of its 
pro-inflammatory actions, such as the counter-regulation of glucocorticoids (123), 
neutrophil priming (124) and the upregulation of metalloproteinases-1 and -3 (123-
125). Although this motif is conserved in D-DT, differences in the tautomerase 
activity associated with this region are apparent. The lower tautomerase activity of D-
DT might suggest qualitative or quantitative differences in the biological function of 
MIF and D-DT. 
ISO-1 has been shown to inhibit some of MIF’s pro-inflammatory actions, 
such as the production of TNFα, PGE2 and COX-2 in vitro (123), and protection 
against death in an in vivo mouse model of endotoxic shock (81). Therefore, it might 
be suggested that ISO-1 does not have these effects on D-DT. As, to date, D-DT’s 
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biological actions are almost completely unknown these aspects remain to be subject 
for further validation in future. 
 
4.5 Neutralization of D-DT Protects Mice from Endotoxic Shock 
Various studies have identified MIF in host response to LPS, the main virulence 
factor of Gram-negative bacteria. In a murine model of LPS-induced endotoxemia, 
MIF is rapidly released into the bloodstream, presenting a bell-shaped increase of 
MIF concentration that peaks at 8 - 20 hours after LPS challenge (11, 13, 30). 
Utilizing the same endotoxic shock model, injection of recombinant MIF increased 
mice mortality, whereas its neutralization led to mice survival. These results are in 
accord with reports of pro-inflammatory actions of MIF and further demonstrate its 
immunoregulatory role. Recently, D-DT has been identified as a protein released from 
immune cells in response to LPS (116). Likewise, D-DT’s release pattern is similar to 
that of MIF, peaking at 16 hours post pro-inflammatory stimulus. However, cultured 
macrophages release 20-fold more MIF than D-DT. These observations describe 
similarities in the release of MIF and D-DT in response to LPS. However, no data on 
D-DT’s role in an in vivo endotoxic shock model has been published to date. 
In this work, I show that an anti-D-DT antibody protects mice from LPS shock, 
which is analogous to previous reports of MIF neutralization. A specific polyclonal 
antibody targeting murine D-DT was used that has been reported not to have any 
cross reactivity to MIF (116). Hence, these results suggest that D-DT might play a 
similar pro-inflammatory function as MIF. However, these are the first reports of 
neutralization of D-DT and subsequent studies should be conducted to further 
substantiate these results. For example, it would be useful to investigate whether 
neutralization of D-DT leads to reduced pro-inflammatory cytokine production as has 
been reported for MIF. Neutralization of MIF by ISO-1 or absence of MIF in mif-/- 
mice inhibited TNFα release from macrophages after LPS administration (18, 81). 
Very recently, Merk et al. reported that D-DT neutralization prior to LPS injection led 
to a significant reduction of the circulating concentrations of pro-inflammatory 
cytokines (TNFα, IL-1β, INFγ, IL-12p70), as well as to an increased concentration of 
anti-inflammatory IL-10 (87). 
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Moreover, mice survival in experiments using other means of D-DT 
neutralization (e.g., the deletion of the D-dt gene or the use of small molecular 
inhibitors) could be addressed, as various means of MIF neutralization have been 
shown to have positive effects on mice survival. Currently, a D-dt knock-out mouse is 
developed which will serve useful for further investigations of D-DT’s functions in 
vivo (87). Regarding inhibitors, it should be noted, that ISO-1 has not been shown to 
inhibit D-DT’s enzymatic activity. The results of this thesis suggest that pretreatment 
of mice with ISO-1 prior to LPS challenge will not affect D-DT-provoked mortality. 
However, were specific small molecular D-DT inhibitors to become available in the 
future, they might have the potential to increase mice survival in endotoxemia. 
Simultaneous specific inhibition of MIF and D-DT might have the potential to further 
increase mice survival. This combined neutralization of both proteins might have an 
additive or synergistic effect. Taken even further, these results may also have 
therapeutic implications in human sepsis. To gain further understanding of D-DT 
actions, mice mortality could additionally be observed after concurrent intraperitoneal 
injection of recombinant D-DT and LPS. Here, a pronounced mice mortality rate 
would affirm D-DT’s pro-inflammatory action. 
D-DT’s molecular modes of action were not investigated in this thesis. 
However, on a molecular level MIF has been shown to upregulate TLR4 expression 
and, thus, to facilitate the detection of LPS and rapidly induce the production of pro-
inflammatory cytokines that are essential for host defense (37, 56). Investigating the 
molecular cascade triggered by released D-DT in respond to LPS would provide 
further insight into D-DT’s precise functions. 
 
4.5.1 D-DT in Human Sepsis is Promising Research Subject 
In order to transfer the results obtained in mice to humans, it would be useful to 
address human D-DT levels for investigation in future experiments. Similar to mouse 
models of endotoxemia, MIF serum levels have been shown to be significantly higher 
in patients suffering from severe sepsis and septic shock compared to healthy control 
groups (82). A correlation between disease severity and MIF levels has been observed 
(154). Similar results for D-DT would further underline its role in disease 
development in response to Gram-negative bacteria. Recently, function studies of D-
DT revealed that D-DT serum levels correlate with disease severity in sepsis and 
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invasive cancer (87). Anti-MIF treatments have been shown to be beneficial in many 
inflammatory diseases. Yet, my data suggest that these approaches might not be 
complete without considering D-DT’s possible role in disease progression. Thus, 
studying D-DT’s in vivo functions as well as the molecular mechanisms underlying 
these effects might allow for the improvement of established anti-MIF treatments in 
inflammatory disease. 
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5 Summary and Outlook 
Macrophage migration inhibitory factor (MIF) is a pleiotropic immunoregulatory and 
pro-inflammatory cytokine, which plays a pivotal role in the pathogenesis of various 
acute and chronic inflammatory diseases such as septic shock, rheumatoid arthritis, or 
atherosclerosis. For example, endotoxemia studies in mice reveal that MIF 
administration decreases the survival rate, whereas neutralization of MIF improves 
the chances for a beneficial outcome. As mounting evidence suggests that chronic 
inflammation contributes towards a microenvironment that favors tumorigenesis, high 
MIF levels are measured in a variety of human tumors. Additionally, functional 
studies reveal MIF involvement in multiple aspects of tumor progression including 
control of cell proliferation, prevention of apoptosis, and promotion of angiogenesis. 
On a molecular level, MIF is released from inflammatory cells upon stimulation. 
Subsequently, MIF binds to its cell surface receptors, resulting in initiation of defined 
signaling cascades that control local and systemic immune responses. Unlike other 
cytokines, MIF also is a phenylpyruvate tautomerase that converts two non-
physiologic enzymatic substrates, D-dopachrome and p-hydroxyphenylpyruvate 
(HPP). To date, possible relationships between the tautomerase and inflammatory or 
tumor-supportive activities of MIF remain unclear. 
In 1993, D-dopachrome tautomerase (D-DT) was discovered during an 
investigation of melanogenesis. The tertiary structure of D-DT is remarkably similar 
to MIF, identifying D-DT as the only known eukaryotic MIF homologue discovered 
to date. D-DT shares MIF’s tautomerase activity and, thus, both proteins are members 
of the MIF tautomerase superfamily. Despite D-DT’s intriguing similarities to the 
very well studied MIF, there have been very few reports on the biological functions 
and mechanisms of action of D-DT. Recent studies illustrate the individual and 
cooperative actions of MIF and D-DT in non-small cell lung carcinoma and colorectal 
cancer, suggesting a role for D-DT in the progression of neoplasm. As the importance 
of MIF’s contributions to many inflammatory and proliferative processes has now 
been generally accepted, interest in the biological actions of D-DT has increased. It is 
possible that functional characterization of D-DT implies subsequent therapeutic 
consequences and might improve or even complete established anti-MIF treatments. 
This thesis aims at the functional characterization of D-DT. Prior to apoptotic 
studies, I report on cloning D-DT cDNA into a mammalian expression vector and 
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transfecting mammalian fibroblasts and macrophages with the generated plasmid. 
Fluorescence microscopy and Western blotting confirm cell transfection and D-DT 
overexpression. My successive data demonstrates that D-DT does not exhibit anti-
apoptotic effects upon nitric oxide-induced apoptosis in transfected macrophages. For 
the first time, this suggests contrary effects of D-DT in comparison to MIF. Yet, it is 
important to note that MIF acts anti-apoptotically in the same experimental setting, 
which is in accord with previous reports of MIF’s functions. Moreover, in a 
subsequent cell survival study of D-DT, I was able to illustrate that D-DT enhances 
macrophage viability to a more pronounced extent than MIF. Interestingly, my data 
further show that simultaneous treatment of cells with MIF and D-DT increases 
macrophage viability even more, which suggests additive effects of both proteins. 
These observations lead to the conclusion that MIF and D-DT may not exhibit 
identical functions. D-DT may even have non-agonistic or antagonistic effects in 
certain settings. Because my results suggest additive effects of MIF and D-DT, they 
provide first evidence of the importance of studying MIF’s and D-DT’s combined 
actions in the future. In addition, I am able to characterize D-DT as a protein that 
tautomerizes the substrate HPP and, thus, possesses analog enzymatic activity to MIF. 
However, quantitative differences in the tautomerization rate become evident between 
different mammalian homologues of D-DT. Other enzymatic studies have revealed 
that the covalent MIF inhibitor 4-IPP also inhibits the tautomerase activity of D-DT, 
whereas D-DT is not susceptible to ISO-1. Taken together, these results demonstrate 
general enzymatic similarity between MIF and D-DT, which is most likely a 
consequence of previously reported structural homology. However, MIF and D-DT 
differ in their susceptibility to enzymatic inhibitors. Moreover, my thesis 
demonstrates first insight into D-DT’s in vivo role in a murine model of endotoxic 
shock. I show that neutralization of D-DT has a protective effect in the LPS-shock 
model. This finding accords with results reported for MIF and, therefore, suggests 
analog functions of D-DT in this context. Taken together, my data demonstrate in 
most cases fairly similar, but also contrary biologic functions of MIF and D-DT. The 
precise therapeutic consequences of these findings were beyond the scope of this 
thesis, but my results provide first hints in this direction. As this is one of the first 
approaches to determine D-DT’s role in disease, continuative investigations need to 
be conducted to further validate these observations. 
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